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The Role of K63-linked Ubiquitination Cycles in Akt Kinase Activation
Publication No. ________________
Wei-Lei Yang, M.S.
Supervisory Professor: Hui-Kuan Lin, Ph. D.
Akt (also known as protein kinase B) serves a central regulator in PI3K/Akt
signaling pathways to regulate numerous physiological functions including cell
proliferation, survival and metabolism. Akt activation requires the binding of Akt to
phospholipid PIP3 on the plasma membrane and subsequent phosphorylation of Akt by
its kinases. Growth factor-mediated membrane recruitment of Akt is a crucial step for
Akt activation. However, the mechanism of Akt membrane translocation is unclear.
Protein ubiquitination is a significant posttranslational modification that controls many
biological functions such as protein trafficking and signaling activation. Therefore, we
hypothesize that ubiquitination may be involved in Akt signaling activation.
We have demonstrated that Akt could be conjugated with non-proteolytic K63linked ubiquitination by TRAF6 ubiquitin E3 ligase. This modification on Akt was
required for membrane recruitment, phosphorylation and activation of Akt in response to
growth factor stimulation. The human cancer-associated Akt E17K mutant exhibited an
increase in K63-linked ubiquitination, which contributes to the enrichment of membrane
recruitment and phosphorylation of Akt. Thus, we conclude that K63-linked
ubiquitination is a critical step for oncogenic Akt activation and also involved in human
cancer development.
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Notably, the process of protein ubiquitination can be reversed by deubiquitinating
enzymes (DUBs), which play a critical role to terminate signaling activation induced by
ubiquitination. To further investigate how ubiquitination cycles regulate Akt activation,
we have identified that CYLD as a DUB for Akt, and CYLD inhibited growth factorinduced ubiquitination and activation of Akt. Under serum-depletion condition, CYLD
interacts with Akt and keep Akt under inactive state by directly removing K63-linked
ubiquitination of Akt. CYLD disassociates with Akt upon growth factor stimulation,
thereby allowing E3 ligases to induce ubiquitination and activation of Akt. We also
demonstrated that CYLD deficiency promoted cancer cell proliferation, survival, glucose
metabolism and human prostate cancer development. Therefore, we conclude that CYLD
plays a critical role for negatively regulating Akt signaling activation through
deubiquitination of Akt.
In summary, this study delineated the important mechanism of cycles of
ubiquitination and deubiquitination of Akt in regulating membrane translocation and
activation of Akt, and TRAF6 and CYLD as central switches for these processes.
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Chapter 1
Introduction

1

1-1. Akt/Protein Kinase B (PKB)
Akt (also known as protein kinase B) is a serine/threonine protein kinase which
belongs to the AGC (cAMP-dependent, cGMP-dependent and protein kinase C) protein
kinase family and shares extensive homology of kinase domain with protein kinases A, G
and C (1). Akt is originally discovered as the cellular homolog of oncogene (v-Akt) within
the mouse leukemia virus AKT8 (2). It consists of three highly homologous isoforms:
Akt1, Akt2 and Akt3 (encoded by PKBα, PKBβ and PKBγ genes, respectively) (3). Each
individual AKT isoform has been widely studied and reported to be involved in regulating
different cellular processes. Through careful phenotypic analysis of distinct Akt isoformspecific knockout mice, these studies found that Akt1 may play an important role in cell
survival as Akt1 knockout mice had smaller body size and Akt1-/- mouse embryonic
fibroblasts (MEFs) exhibited greater rate of apoptosis than their wild-type counterparts (4,
5). Interestingly, Akt2 is reported to be involved in regulating glucose homeostasis as
evident by aberration in glucose balance and type II diabetes-like phenotype in Akt2
knockout mice and consistently, Akt2-/- MEFs displayed impaired glucose utilization (6, 7).
Akt3 knockout mice exhibited impaired brain and nervous system development, suggesting
Akt3 may be involved in the development of nervous system (8).
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1-2. The PI3K/Akt signaling pathway
Cells respond to a variety of extracellular stimuli, including growth factors or
cytokines. These stimuli modulate cellular functions or homeostasis by engaging their
cognate receptors and triggering respectively downstream signaling cascades. The
phosphatidylinositol 3-kinase (PI3K)/Akt signaling pathway transmits extracellular signals
to the inside of cells (9). Also, it is well-known to play critical role in numerous biological
functions such as growth, survival, migration and metabolism of the cells (1, 3, 9-11).
Expectedly, deregulation of this central signaling pathway is associated with several types
of human diseases, including, type II diabetes and cancers (12).
PI3K comprises the p85 regulatory subunit and p110 catalytic subunit. The p85
subunit contains two Src-homology 2 (SH2) domains and one Src-homology 3 (SH3)
domain, and the p110 subunit possesses a kinase domain to phosphorylate its substrates,
such as the phospholipid phosphatidylinositol (4,5)-bisphosphate [PI(4,5)P2] (9). The
PI3K/Akt pathway is activated by various growth factors, cytokines, or other stimuli
through their cognate receptors (3, 9-11, 13). As shown in Figure 1-1, in response to these
extracellular stimuli, PI3K phosphorylates the inositol ring of PI(4,5)P2 at the D-3 position
to form PI(3,4,5) P3, which is essential for recruiting and activating Akt kinase on the
plasma membrane (9). The translocation of Akt from the cytosol to the plasma membrane
requires the pleckstrin homology (PH) domain at the N-terminal of Akt binding to
PI(3,4,5)P3 phospholipid on the membrane (9, 11). In there, phosphoinositol dependent
kinase 1 (PDK1) phosphorylates Akt at Thr308 within its activation loop of the kinase
domain and mammalian target of rapamycin complex 2 (mTORC2) phosphorylates Akt at
Ser473 within its hydrophobic motif of the regulatory domain respectively, resulting in full
3

activation of Akt kinase (11, 14). In contrast, a lipid phosphatase, phosphatase and tensin
homolog (PTEN) can negatively regulate the PI3K/Akt signaling pathway by
dephosphorylating PI(3,4,5)P3 at the D3 position of the inositol ring (15-17).

4

Figure 1-1. The model of growth factor
factor-mediated
mediated phosphorylation and activation of
Akt.
Growth factor receptor kinase is activated by binding to cognate growth factor. Activated
growth receptor further activates PI3 Kinase. PI3 Kinase phosphorylates PIP2 to generate
PIP3 phospholipid on membrane. PIP3 induces cytosolic inactive Akt translocation to the
membrane
brane and interact with PIP3 through the PH domain of Akt. Two kinases PDK1 and
mTOR complex 2 phosphorylate Akt at Thr308 and Ser473 respectively, to allow full
activation of Akt. Although it is well known that membrane translocation of Akt is a
critical step for Akt activation, the detailed mechanism remains unclear.
(Adapted from Cell Cycle. 1;9(3):487
1;9(3):487-9725
9725 (2010). Reprinted with permission from
Landes Bioscience.)

5

1-3. Phosphorylation cycles of Akt determines Akt kinase activity.
The activity of Akt is tightly regulated by phosphorylation and dephosphorylation
cycles of Akt molecule, which serve as molecular switches to turn on/off the Akt activation.
As abovementioned, full activation of Akt relies on the phosphorylation by PDK1 and
mTORC2 at Thr308 and Ser473 of Akt, respectively (14, 18-20). Phosphorylation of Akt at
Thr308 determines its kinase activity directly while phosphorylation at Ser473 alone does not
contribute to Akt activation (21). However, dephosphorylation of Akt at both Thr308 and
Ser473 causes the termination of full Akt activation, suggesting that Ser473 may play an
important role to facilitate Akt phosphorylation at Thr308.
Protein phosphatase 2A (PP2A) dephosphorylates Akt at Thr308, whereas PH domain
leucine-rich repeat protein phosphatase (PHLPP) dephosphorylates Akt at Ser473 to inhibit
Akt activity (Fig. 1-2) (22-26). Notably, a higher regulatory complexity of Akt activity is
mediated through Akt associating proteins, for example, dephosphorylation of Akt by
PHLPP requires FK506 binding protein 51 (FKBP51) which works as a scaffold for
association of Akt with PHLPP (27). Similarly, tumor suppressor promyelocytic leukemia
protein (PML) has also been shown to regulate Akt activation through associating with Akt
and PP2A to form a protein complex. This complex promotes PP2A-mediated
dephosphorylation of Akt at Thr308, suggesting that PML serves as a coordinator in the
nuclear tumor suppressor network for dephosphorylation of nuclear Akt (Fig. 1-2) (28).
In response to dopamine stimulation in neurons, PP2A also interacts with another
scaffold protein, β-arrestin-2, to form Akt/β-arrestin-2/PP2A signaling complex that
dephosphorylates Akt (Fig. 1-2) (29). Compared with its negative role in the activation of
Akt in neurons, a recent study demonstrated that β-arrestin-2 is required for
6

phosphorylation and activation of Akt in response to insulin stimulation in muscles (30). βarrestin-2 recruits both Akt and Src to the activated insulin receptors, which is essential for
tyrosyl phosphorylation of Akt (Fig. 1-2) (30). Several studies showed that Src-mediated
tyrosyl phosphorylation of Akt at Tyr315 and Tyr326 is a prerequisite step for
phosphorylation of Akt at Thr308 and Ser473 and further activation of Akt (30-34).
Importantly, deficiency of β-arrestin-2 in mice shows defect in phosphorylation of Akt
and is associated with development of type 2 diabetes, whereas overexpression of βarrestin-2 in mice enhances activation of Akt and improves the diabetes phenotype (30).
This study suggests that β-arrestin-2 is an important scaffold molecule, which forms a
signaling complex with Akt and Src to regulate Akt activation and insulin sensitivity (30).
Therefore, these studies support the notion that β-arrestin-2 has diverse regulatory roles in
the activation of Akt signaling which is dependent on different stimuli and tissue types.
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Figure 1-2. The activity
dephosphorylation of Akt.

of

Akt

is

regulated

by

phosphorylation

and

β-arrestin-22 recruits Src and Akt to the activated insulin receptor, and phosphorylation of
Akt at Tyr315 and Tyr326 by Src is a prerequisite step for Akt Thr308 and Ser473
phosphorylation induced by PDK1 and mTORC2, respectively, leading to the full
activation of Akt. Akt Thr308 dephosphorylation is triggered by PP2A phosphatase. PML or
β-arrestin-2 recruits
its PP2A and facilitates Akt Thr308 dephosphorylation.
Dephosphorylation of Akt at Ser473 is induced by PHLPP phosphates. The adaptor protein
FKBP51 recruits PHLPP to elicit Akt dephosphorylation at Ser473.
(Adapted from Cell Cycle. 1;9(3):487
1;9(3):487-9725 (2010).. Reprinted with permission from
Landes Bioscience.)
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1-4. Akt regulates various downstream substrates and biological functions.
Akt kinase plays a central role in the regulation of a variety of biological functions
ranging from cell survival, growth, metabolism to migration by phosphorylating a broad
spectrum of downstream substrates (Fig. 1-3) (1). It is well recognized that Akt inhibits
cell apoptosis by promoting phosphorylation of pro-apoptotic proteins such as Bad and
Foxo3a (9, 11). Furthermore, various oncogenic proteins involved in cell cycle regulation
and tumorigenesis, including murine double minute (MDM2), inhibitor of nuclear factor
kappa-B kinase subunit alpha (IKKα) and S-phase kinase-associated protein 2 (Skp2) E3
ligase are also phosphorylated and regulated by Akt kinase (35-41).
Additionally, Akt has been reported to phosphorylate and subsequently inactivate
mTOR complex inhibitor tuberous sclerosis 2 (TSC2), resulting in activation of the mTOR
signaling pathway to control cell proliferation and protein synthesis (42, 43). Importantly,
Akt is also shown to regulate glucose metabolism through phosphorylating and inhibiting
the activity of glycogen synthase kinase 3β (GSK3β) (44). Lastly, numerous substrates of
Akt have been reported to be involved in cell migration, for example, p21 proteinactivated kinase 1 (PAK1), ArfGAP with coiled-coil, ankyrin repeat and PH domains 1
(ACAP1), Skp2 and Girdin/APE are known to be phosphorylated by Akt (38, 45-47)
However, further evidence is needed to determine if phosphorylation of these proteins by
Akt is necessary for Akt-mediated cell migration.

9

3. Akt regulates numerous biological functions by phosphorylating distinct
Figure 1-3.
protein substrates.
Akt protects cells from apoptosis by phosphorylating and inactivating proapoptotic
proteins, such as Bad and Foxo3a. Akt regulates cell growth and prot
protein
ein translation by
phosphorylating and inactivating TSC2, resulting in activation of the mTOR pathway. Akt
regulates cell cycle progression and tumorigenesis by phosphorylating and activating
oncogenic proteins, such as Skp2, Mdm2 and IKK
IKKα.. Akt can orchestrate
orchest
glucose
metabolism by regulating the activity of GSK3
GSK3β.. Akt may also regulate cell migration by
inducing the phosphorylation and activation of Skp2, Girdin/APE, ACAP1 and PAK1.
(Adapted from Cell Cycle. 1;9(3):487
1;9(3):487-9725
9725 (2010). Reprinted with permission
permissi
from
Landes Bioscience.)
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1-5. The implication of PI3K/Akt signaling pathway in human cancer development
It has been well recognized that PI3K/Akt signaling plays a significant role in human
cancer development. For example, a study in the prostate cancer model demonstrated that
overexpression of insulin-like growth factor-binding protein-5 (IGFBP-5), stimulated
activation of the PI3K/Akt pathway and accelerated progression of the prostate cancer
from androgen-dependent to androgen-independent type (48).
Abnormal activation of Akt is detected in a variety of human cancers, and
significantly, three Akt isoforms, Akt1, Akt2 and Akt3 have been reported to be
overexpressed in various human cancers, such as breast cancer, liver cancer, colorectal
cancer and melanoma (49-54). Recent studies reported that spontaneous Akt1 mutations
associated with hyper-activation of Akt are observed in human cancers including breast
cancer, ovarian cancer and colorectal cancer (55-61). The functional role of Akt in human
cancer development and progression has been evaluated by several animal tumor models.
For instance, Pten+/- mice with abnormal activation of Akt were found to develop multiple
tumors, whereas the phenotype was reversed by deficiency of Akt1 (62, 63). Furthermore,
constitutively active Akt1 specific expression in prostate of mice caused prostate
intraepithelial neoplasia (PIN), a pre-malignant prostate cancer (64, 65). These studies
highlight the important role of the PI3K/Akt signaling pathway in human cancer
development and progression.
For intervention, several research groups have developed small molecule inhibitors to
target this pathway and tested the cancer therapeutic effect of these inhibitors in clinical
trials (66). However, direct targeting of this crucial signal pathway is expected to raise
severe side effects such as diabetes and cardiac malfunctions (66). Therefore, a
11

comprehensive understanding of PI3K/Akt signaling pathway is crucial in helping us to
develop innovative and effective strategies for human cancer therapies with minimum side
effects. Although it is well known that the recruitment of cytosolic Akt to the plasma
membrane is a critical step for Akt phosphorylation and activation (12), the underlying
mechanism involved in Akt translocation to the membrane is still a mystery. It is possible
that other types of post-translational modification, such as acetylation, ubiquitination, or
sumoylation, may regulate the process of Akt membrane localization and activation.
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1-6. The role of ubiquitination in protein degradation and other functions
Protein ubiquitination is a common post-translational modification in cell that
regulates a variety of cellular functions (67-69). The function of ubiquitination is initially
recognized as a signature to mark proteins for degradation through 26S proteasomedependent manner (70). However, more and more studies demonstrate that ubiquitination
is also involved in non-proteolytic functions such as receptor endocytosis, protein
trafficking, DNA damage repair and activation of certain signaling pathways such as IκB
kinase/nuclear transcription factor kappaB (IKK/NFκB) signaling pathway (Fig. 1-4) (12,
67, 71). These ground-breaking findings shed light on the critical role of ubiquitination in
regulating numerous biological functions through distinct signal transduction pathways.
Ubiquitin is a small regulatory molecule which contains 76 amino acid polypeptides.
It is highly evolutionarily conserved from prokaryote to primate (72). Ubiquitination is a
covalent reaction by which ubiquitin(s) is/are attached to one or more lysine (K) residues
of protein substrates (72). The process of ubiquitination involves three major steps, and
each step is facilitated by distinct classes of enzymes. In the first step, ubiquitin is activated
by ubiquitin activating enzyme (E1). Activated ubiquitin is transferred from E1 to
ubiquitin conjugating enzyme (E2). Subsequently, ubiquitin ligase (E3) brings ubiquitinconjugated E2 and a protein substrate together, following by the transfer of the ubiquitin
from E2 to the targeted protein substrate (Fig. 1-4) (73). At present, two E1s,
approximately 50 E2s and 600 E3s have been identified in human genome (67).
The fate of ubiquitinated protein is determined by types of ubiquitination on protein.
Currently, three major types of ubiquitination in cells are reported, namely monoubiquitination, mono-ubiquitination at multiple sites and poly-ubiquitination. Mono13

ubiquitination occurs when a single ubiquitin attaches on its substrate, which is associated
with protein endocytosis, endosomal sorting, DNA repair and histone regulation (74).
When ubiquitination on several lysine residues of substrate takes place, it is termed
multiple-ubiquitinations, which has been associated with endocytosis (74). Ubiquitin
contains seven lysine residues (K6, K11, K27, K29, K33, K48 and K63), all of which may
be involved in polyubiquitin chain formation in vivo (Fig. 1-4) (75). The function of K48linked and K63-linked polyubiquitin chains are the best characterized at present. The K48linked polyubiquitin chain is first identified to be recognized by the 26S proteasome for
protein degradation (72). In contrast, the K63-linked polyubiquitin chain serves as a
molecular platform for protein-protein interaction which is important for non-proteolytic
functions including receptor endocytosis, DNA damage repair, protein trafficking and
signaling activation (67-69, 76, 77). Although other types of ubiquitin modifications are
also observed, the exact role they play is less understood. Recent studies suggested that
they can be involved in either protein degradation or non-proteolytic functions (73, 78, 79).
Theoretically, the E2 determines the type of ubiquitination to be formed on the
substrate, while the E3 determines the substrate specificity for ubiquitination (72). Most of
E2 members mediate the K48-linked polyubiquitination. However, one of E2 members
ubiquitin-conjugating enzyme E2N (UBC13/UBE2N), with the facilitation of its cofactor
ubiquitin-conjugating enzyme E2 variant 1 (UEV1A), is a major E2 that induce K63linked polyubiquitination (75). The E3 family members can be categorized into two major
groups based on distinct ubiquitination mechanisms: [1] comprising a homologous to the
E6-AP carboxyl terminus (HECT) domain; [2] consisting of a really interesting new gene
(RING) or RING-like domain such as U-Box and plant homeo domain (PHD) (67). Most
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of known E3 members mediate K48-linked polyubiquitination on substrates. With the
exception of a few of E3 members, such as homologous to E6AP carboxyl terminus
homologous protein 9 (HectH9), mouse double minute 2 (MDM2) and cellular inhibitor of
apoptosis protein 1/2 (c-IAP1/2), which promote not only K48-linked polyubiquitination,
but also K63-linked polyubiquitination (67, 80-83). At present, TNF receptor activating
factor 6 (TRAF6) and ring finger protein 8 (RNF8) are known E3s that selectively regulate
K63-linked polyubiquitination important for the innate immune response and DNA
damage response, respectively (67, 81, 82).
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4. Ubiquitination regulates protein degradation or activation.
Figure 1-4.
Ubiquitination reaction involves three enzymes. Ubiquitin is activated by the E1 and is
subsequently transferred to the E2. The E3 provides substrate specificity and bringing the
th
targeted substrate to the E2, resulting in protein ubiquitination. Ubiquitin consists of seven
lysine residues, and the site involved in ubiquitination chains formation dictates the diverse
fates of proteins. The K48-linked
linked ubiquitination is recognized bby
y the 26S proteasome and
results in protein degradation. In contrast, the K63
K63-linked
linked ubiquitination regulates receptor
endocytosis, DNA damage repair, protein trafficking and signaling activation. Other types
of polyubiquitin chain may be involved in eithe
eitherr protein degradation or non-proteolytic
non
functions.
(Adapted from Cell Cycle. 1;9(3):487
1;9(3):487-9725
9725 (2010). Reprinted with permission from
Landes Bioscience.)
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1-7. Ubiquitination regulates degradation of Akt.
Akt activity is well-known to be modulated by phosphorylation/dephosphorylation
modification. The protein stability and abundance of Akt are also critical in determining
Akt activity. Akt has a relatively long half-life with its protein stability controlled by
numerous stimuli (84). Heat-shock protein 90 (HSP90), a molecular chaperone, binds to
Akt and maintain the stability of Akt. Cells treated with 17-allylamino-17demethoxygeldanamycin (17-AAG), a HSP90 inhibitor, triggers Akt ubiquitination and
proteasome-mediated degradation (84, 85). Following study found that carboxyl terminus
of Hsc-70-interacting protein (CHIP) promotes ubiquitination of Akt and knockdown of
CHIP protein expression blocks 17-AAG-mediated Akt degradation (86). This finding
suggests that CHIP is essential for HSP90-mediated Akt degradation.
Furthermore, other study demonstrated that mTORC2-mediated phosphorylation of
Akt at Thr450 is required for Akt stability. It has been shown that knockdown of mTOR
complex or its component Sin1 decreases phosphorylation of Akt at Thr450, followed by
augmenting ubiquitination and degradation of Akt (87). Moreover, a recent study
demonstrated that an E3 ligase tetratricopeptide repeat domain 3 (TTC3) is essential for
ubiquitination and degradation of Akt (88, 89). In the nucleus, TTC3 showed proteinprotein interaction with the active form but not inactive form of Akt, (88, 89). This finding
suggested that ubiquitination of Akt by TTC3 may be a critical step to terminate Akt
activity in the nucleus. Remarkably, Akt promoted phosphorylation of TTC3 at Ser378 and
this phosphorylation is critical for enzymatic activity of TTC3 (88, 89), suggesting a
possible feedback loop to negatively regulate Akt activity. In addition, Breast cancer type 1
(BRCA1) tumor suppressor is also found to associate with active Akt and to further
17

enhance ubiquitination and degradation of Akt (90). In summary, these recent studies
suggest that CHIP, TTC3 and BRCA1 E3 ligases induce K48-linked ubiquitination of Akt
to trigger Akt degradation and subsequently terminate activation of Akt signaling.
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1-8. Ubiquitination regulates endocytosis and trafficking of growth factor receptors.
Ubiquitination is known to control endocytosis and membrane localization of receptor
proteins, including epidermal growth factor receptor (EGFR), insulin-like growth factor-1
receptor (IGF-1R) and prolactin receptor (91-93). For example, recent study showed that in
response to different concentrations of insulin-like growth factor-1 (IGF-1), IGF-1R was
internalized into lipid raft compartments and the early endosome in the cell (94). The result
suggested that lower concentration of IGF-1 promotes K63-linked ubiquitination of IGF1R, whereas higher concentration of IGF-1 triggers K48-linked ubiquitination of IGF-1R
(94).
MDM2 has been identified to promote K63-linked ubiquitination of IGF-1R and
triggers the internalization of IGF-1R to the early endosome. In contrast, casitas B-lineage
lymphoma (c-Cbl) has been found to elicit K48-linked ubiquitination of IGF-1R and
initiates the internalization of IGF-1R to the lipid raft. Furthermore, neural precursor cell
expressed

developmentally down-regulated

4-1

(NEDD4-1)

also

promotes

the

ubiquitination of IGF-1R and controls internalization of IGF-1R to the early endosome and
lipid raft (92). The results of these studies propose that distinct types of ubiquitination may
control the trafficking of IGF-1R to different cellular compartments. However, it is still a
puzzle if ubiquitination of IGF-1R through these E3 ligases directly controls the trafficking
and signaling transduction of IGF-1R.
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1-9. K63-linked ubiquitination regulates activation of protein kinases.
The activity of protein kinase is well recognized to be controlled by phosphorylation.
Recently, the K63-linked ubiquitination has been found to be involved in regulating
activation of some protein kinases, such as toll-like receptor (TLR) and transforming
growth factor-β (TGF-β) signaling pathways (67). TGF-β activating kinase-1 (TAK1) is a
central modulator that mediates activation of nuclear factor-κB (NF-κB), p38 and c-Jun Nterminal kinase (JNK) signaling pathways in response to activation of TLR and TGF-β
signaling pathways (67).
More recent studies demonstrated that TAK1 can be conjugated with K63-linked
ubiquitination by TRAF6 E3 ligase. Upon TGF-β signaling stimulation, TRAF6 promotes
K63-linked ubiquitination of TAK1 at lysine 34 (95, 96). This type of modification is
required for auto-phosphorylation and following activation of TAK1 (95). However, the
mechanism underlines how ubiquitination-mediated activation of TAK1 is still unknown.
The proposed models suggest two concepts: one is that K63-linked ubiquitination of TAK1
may trigger conformational change of TAK1, which then promotes auto-phosphorylation
and activation of TAK1. Otherwise, K63-linked ubiquitination may work as a platform to
recruit TAK1-binding protein 2 (TAB2)/TAB3 cofactors, which then initiates subsequent
activation of TAK1. Indeed, a recent study supported the later concept that the
ubiquitination of TAK1 functions as a scaffold to recruit mitogen-activated protein kinase
kinase kinase 3 (MEKK3) to activate the mitogen-activated protein kinase (MAPK)
signaling pathway (97).
Mixed linage kinase 3 (MLK3) is another example in which ubiquitination controls
activation of protein kinase. MLK3 is a family member of mitogen-activated protein kinase
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kinase kinase (MAP3K), which is activated by growth factors, stress and the proinflammatory cytokines including tumor necrosis factor (TNF) and interleukin-1 (IL-1) to
activate multiple MAPK signaling pathways. One recent study demonstrated that TRAF6
promotes K63-linked ubiquitination of MLK3 and this type of modification is a crucial
step for activation of MLK3 (98).
Additional studies showed that K63-linked ubiquitination of inhibitor of NF-κB
kinase subunit γ (IKKγ), also known as NF-κB essential modulator (NEMO) is also
required for activation of IKK complex, which is an upstream kinase that promote
phosphorylation and subsequent degradation of inhibitor of NF-κB (IκB) (67, 99). The
degradation of IκB separates transcription factor NF-κB from a heterodimer complex with
IκB and promotes nuclear translocation and downstream gene expression of NF-κB (99).
The association of the regulatory subunit IKKγ with IKKα and IKKβ is critical for
activation of IKK complex although IKKγ does not have kinase activity (99). Recently, an
ubiquitin-binding protein, Abin-1, has been shown to induce K27-linked ubiquitination and
subsequent degradation of IKKγ, therefore, IKK complex activity and activation of NF-κB
were inhibited (100). However, upon stimulation of T-cell receptor signaling, TRAF6
promoted K63-linked ubiquitination of IKKγ which is required for activation of IKK
complex and NF-κB (101-103).
In summary, these above studies suggest that K63-linked ubiquitination may play a
critical role for activation of a variety of protein kinases involving in several important
signaling transduction pathways in the cell.
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1-10. TRAF6 E3 ligase controls important signal transduction pathways.
TRAF6 is a well characterized ubiquitin E3 ligase containing a RING domain. It acts
as a central mediator in regulating several signal transduction pathways, including Tolllike receptor 4 (TLR4) and interleukin-1 receptor (IL-1R) signaling pathway, to activate
NF-κB signaling (67, 76, 99). Upon stimulation with ligands of TLR4/IL-1R such as
lipopolysaccharide (LPS) or IL-1, TRAF6 is recruited to the receptor activated by IL-1
receptor-associated kinase 4 (IRAK4) /IRAK1/IRAK2 protein complex by promoting its
oligomerization and auto-K63-linked ubiquitination (67, 76, 99). The K63-linked
ubiquitination of TRAF6 has been suggested to function as a scaffold to associate with the
protein kinase complex TAB2/TAB3/TAK1 (67, 99). The interaction of TAK1 with
TAB2/TAB3 promotes auto-phosphorylation of TAK1, consequently activating TAK1
kinase. TAK1 then phosphorylates IKKβ to promote the activation of IKK complex
including IKKα, IKKβ and the regulatory protein IKKγ (also known as NEMO) (67, 99).
Active IKK complex therefore phosphorylates IκB and promotes K48-linked
ubiquitination and degradation of IκB (67, 99). As a result, a subunit of NF-κB, p65,
becomes free from IκB and moves into the nucleus, where it can trigger transcription of
numerous target genes critical for inflammation and the innate immune response (67, 76,
99).
Studies utilizing Traf6-/- cells showed that in addition to LPS and IL-1, TRAF6 is also
essential for CD40 ligand (CD40L), receptor activator of NF-κB ligand (RANKL) and
tumor growth factor-β (TGF-β)-induced activation of NF-κB (Fig. 1-5) (104). TRAF6 is
also involved in TGF-β-mediated phosphorylation and activation of p38 signaling pathway,
but not traditional phosphorylation of SMAD family member 2/3 (Smad2/3) signaling
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pathway (95, 96, 105). TGF-β induces the interaction of TRAF6 with TGF-β receptor I and
further promotes ubiquitination and activation of TRAF6, in turn stimulating K63-linked
ubiquitination and activation of TAK1 and subsequent phosphorylation and activation of
p38 and JNK signaling pathways to regulate cell growth arrest and apoptosis (95, 96, 105).
In addition, TRAF6 is shown to be essential for TGF-β-mediated epithelial-mesenchymal
transition (EMT) and cell apoptosis (Fig. 1-5) (95, 96, 105). These results suggest that
TRAF6 may have a dual function in TGF-β-mediated tumor suppression and cancer
metastasis.
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5. TRAF6 regulates multiple signal transduction pathways involved in the
Figure 1-5.
plethora of biological functions.
TRAF6 is a critical mediator for NF
NF-κB
B activation upon the engagement of CD40L,
TRANCE, LPS and IL-11 to their receptors, in turn regulating inflammation and innate
immune response. TRAF6 is activated by TGF
TGF-β/TGF-β receptor
or and is required for TGFTGF
β-mediated
mediated p38 and JNK activation. The activated p38 and JNK positively regulate cell
apoptosis and EMT. Interestingly, TRAF6 is also activated upon the binding of IGF-1
IGF to
IGF-11 receptor and regulates cell survival by inducing A
Akt activation.
(Adapted from Cell Cycle. 1;9(3):487
1;9(3):487-9725
9725 (2010). Reprinted with permission from
Landes Bioscience.)
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1-11. Ubiquitination of protein is reversible by deubiquitination.
Like other post-translational modifications, the process of ubiquitination is also
reversible. Ubiquitination on protein can be removed by the deubiquitinating enzymes
(DUBs), which function in opposition to the ubiquitin E3 ligases (106). One of the
hallmarks for the DUBs is that the ubiquitin binding domains (UBDs) are found in most
DUBs, such as the zinc-finger ubiquitin-specific protease domain (ZnF-UBP domain), the
ubiquitin-interacting motif (UIM), the ubiquitin-associated domain (UBA domain) and the
ubiquitin-like folds (UBL folds) (106, 107), therefore the DUBs are able to recognize and
bind to the ubiquitinated protein substrates and remove ubiquitination on substrates. The
function of DUB is determined by the structure of UBD, which specifically interact with
the different types of ubiquitinated substrates and then triggers DUB enzyme activity to
deubiquitinate substrates (107).
There are approximately 90 DUBs in human genome and they can be divided into five
classes based on their sequence and structural similarity, including ubiquitin-specific
protease (USP), ubiquitin C-terminal hydrolase (UCH), ovarian tumor-like protease (OTU),
Josephin and JAB1/MPN/MOV34 metalloenzyme (JAMM/MPN+) (106, 107). Among
them, the USP, UCH, OUT and Josephin families belong to the cysteine protease that
relies on the cysteine residue as the catalytic center. Only the JAMM/MPN+ family are the
zine metalloprotease which requires a metal ion, such as zinc, for its activity and catalytic
mechanism (106, 107). DUBs play several important biological functions in the cell: [1]
Ubiquitin precursor processing: DUBs process ubiquitin linear polyprotein precursor into
free ubiquitin; [2] Ubiquitin recycling: DUBs remove K48-linked polyubiquitin chain from
substrates before substrates are degraded by the 26S proteasome to release free ubiquitin;
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[3] Regulation of substrate degradation: DUBs remove K48-linked polyubiquitin chain
from substrates to rescue substrate degradation by 26S proteasome; [4] Regulation of
substrate activity: DUBs can remove mono-ubiquitin or non-proteolytic polyubiquitin
chain from substrates to terminate substrate activity; [5] Ubiquitin chain editing: DUBs
edit ubiquitin chain linkage type (e.g., K48-linked to K63-linked) on the substrate by
removing one ubiquitin chain linkage type before elongation of a second chain (106, 107).
So far, among DUB families, the USP family members are the well-studied with known
mechanisms and protein substrates characterized.
At present, the DUBs are well recognized to play significant roles in regulating critical
oncogenic and tumor suppressor signal transduction pathways including PTEN, p53 and
NF-κB signaling pathways (15, 67). For instance, USP7, also known as herpes virusassociated ubiquitin-specific protease (HAUSP), interacts with the ubiquitinated PTEN in
the nucleus and promotes deubiquitination and subsequent nuclear export of PTEN (108).
USP7 also binds to polyubiquitinated p53 and induces deubiquitination and following
stabilization of p53 (109). Nevertheless, recent studies suggested that USP7 deficiency
unexpectedly increases stabilization of p53 (110, 111). This phenomenon may be
explicated in part by the fact that USP7 also interacts with polyubiquitinated MDM2 and
increases stabilization of MDM2 (112-115). Therefore, these studies suggest that USP7
may play an oncogenic function which can facilitate human cancer development. In
consistent with this concept, accumulation of USP7 protein has been found in human
prostate cancer and UPS7 deficiency further inhibits cell proliferation (108).
Other USP family member, USP10, is also a DUB for deubiquitination of p53. MDM2
is formerly recognized to be an E3 ligase for ubiquitination of p53 and induces nuclear
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export and degradation of p53 (116). USP10 promotes deubiquitination of p53 and reduces
MDM2-indued nuclear export and degradation of p53 (117), suggesting that USP10 may
have a tumor suppressive function through stabilizing p53. In line with this concept,
expression of USP10 is usually deficient in renal cell carcinoma, and overexpression of
USP10 inhibits normal cell transformation and tumorigenesis through regulating p53dependent mechanism (117).
Many studies have demonstrated that USPs control ubiquitination and degradation of
oncogenic proteins. For instance, USP28 interacts with Myc and leads to deubiquitination
of Myc and further preventing Myc from degradation (118, 119). Notably, overexpression
of USP28 has been found in several human cancers, and USP28 deficiency suppresses cell
proliferation and transformation (119), suggesting that USP28 may have an oncogenic
function. In addition, one recent study showed that USP2 is a DUB for deubiquitination of
cyclin D1 and MDM2. USP2 interacts with cyclin D1 and MDM2 and induces
deubiquitination and stabilization of cyclin D1 and MDM2, and USP2 deficiency leads to
reduced protein expression of cyclin D1 and MDM2, resulting in suppression of cell
proliferation (120, 121).
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1-12. The role of DUBs in regulating NF-κ
κB signaling pathways
Cylindromatosis (CYLD) and A20 proteins are well-known DUBs that play negative
regulatory roles in NF-κB signaling activation by promoting deubiquitination of critical
modulators such as TRAF6 and IKKγ (122, 123). CYLD has been found to be frequently
mutated in patients associated with some inherited diseases including familial
cylindromatosis, which is characterized by development of multiple benign tumors from
skin appendages (cylindromatosis) (122, 124). CYLD exhibits specific deubiquitinase
activity toward K63-linked ubiquitination of critical modulators in NF-κB signaling
activation. These include TRAF2, TRAF6 and NEMO to decrease their activities in
regulating activation of NF-κB (67, 122, 125-128). In addition, CYLD also inhibits
activation of TAK1 and IKK complex through cleaving free unanchored K63-linked
ubiquitination chains (129). Notably, analyses of the genetically engineered mouse model
of CYLD has corroborated that CYLD has tumor suppressive functions in vivo. Several
studies demonstrated that Cyld-null mice are highly sensitive to chemical-induced
tumorigenesis such as skin cancers, colitis and colon cancers (130-133).
CYLD and an E3 ligase ITCH form a protein complex, which removes K63-linked
ubiquitination chain on TAK1 by CYLD and subsequently promotes K48-linked
ubiquitination chain on TAK1 by ITCH, leading to inactivation and degradation of TAK1
and subsequently terminates NF-κB activation (134). This study suggests that different
types of polyubiquitination chains such as K63-linked and K48-linked ubiquitination
chains can be distinctively exploited to regulate activation and inactivation of protein
kinase.
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A20 belongs to the ovarian tumor-like protease (OUT) deubiquitinase family. It
includes an N-terminal OTU-type DUB domain and seven C-terminal zinc fingers (123).
A20 was originally identified as a negative regulator of NF-κB signaling induced by innate
immune signals such as tumor necrosis factor (TNF) and toll-like receptors (135). A20 can
cleave K63-linked ubiquitination on TRAF6, receptor-interacting serine/threonine-protein
kinase 1 (RIP1), RIP2 and IKKγ/NEMO to terminate NF-κB signaling activation (123).
However, the unique feature of this DUB is that it also has E3 ubiquitin ligase activity to
perform ubiquitin chain editing on substrates through replacing the K63-linked
ubiquitination chain with proteasome-targeting K48-linked ubiquitination chain (136). In
recent years, several lines of evidence supported the correlation between A20 and human
cancers. For instance, one study reported that a dramatic loss of A20 expression is found in
cases of non-Hodgkin’s lymphoma, Burkett’s lymphoma and T-cell lymphomas (137).
Another study also demonstrated that inactivating mutations in A20 are found in large
numbers of cases of marginal zone lymphoma (138). Taken together, these data suggest
that A20 is a potential tumor suppressor in human lymphoma by regulating activation of
NF-κB signaling.
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Chapter 2
Materials and Methods

30

2-1. Cell lines and culture
MEFs from Traf6+/+ and Traf6–/– and Cyld+/+ and Cyld-/- mice were prepared as
previously described (104, 139). MEFs, NIH3T3, COS-1, PC-3, DU-145, MDA-MB-231
and 293T cells were purchased from the American Type Culture Collection and cultured in
DMEM containing 10% FBS with and penicillin/streptomycin in 5% CO2 at 37°C.

2-2. Antibodies and reagents
Antibodies against TRAF6, ubiquitin and N-cadherin from Santa Cruz
Biotechnology; antibodies against pan-Akt isoforms, phospho-Akt (Thr308),
phospho-Akt (Ser473), cleaved caspase-3, phospho-Foxo1 (Thr24)/Foxo3a
(Thr32), ERK, phospho-ERK, TSC2, phospho-TSC2 (Ser1462), phosphoGSK3β (S9) and CYLD from Cell Signaling; antibodies against α-tubulin,
β-actin and Flag-tag (M2) from Sigma; antibody against Glut1 from Abcam;
antibody against Glut4 from Millpore; antibody against GSK3β from BD
Transduction Lab; antibody against Xpress-tag from Invitrogen; antibody
against HA-tag from Covance.
Reagents were purchased from the following sources: Dulbecco's
modified Eagle's medium (DMEM) and fetal bovine serum (FBS) from
HyClone; complete protease inhibitor cocktail from Roche; human
recombinant IGF-1 , EGF and N-Ethylmaleimide from Calbiochem; human
recombinant IL-1β from Peprotech; LPS from Sigma; doxorubicin from MP
Biomedicals; cisplatin from ALEXIS Biochemicals; LY294002 and
wortmannin from Cell Signaling; lipofectamine 2000 from Invitrogen.
(From Science, 25 (5944): 1134-1138 (2009) and Science Signaling, 6
(257), ra3. (2013). Reprinted with permission from AAAS.)

2-3. Plasmid DNAs
Flag-TRAF6, Flag-TRAF6 C70A, pGEX-4X1-TRAF6, and pGEX4X1-TRAF6 C70A constructs have been described previously (140). Akt
KD (Akt K179A) and Mdm2 have been described previously (39). (His)6ubiqutin and HA-Akt1 were gifts from Drs. D. Bohmann and M.C. Hung,
respectively. Flag-Smurf2 and Flag-FBW7 were obtained from Drs. J.L.
Wrana and M.H. Lee, respectively. Flag-c-IAP1 and Flag-c-IAP2 were
obtained from Dr. X. Yang. Myc-ITCH and HA-Cbl-b constructs were from
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Drs. A.M. Weissman and S. Lipkowitz, respectively. HectH9, (His)6ubiqutin K6R, (His)6-ubiqutin K11R, (His)6-ubiqutin K48R, and (His)6ubiqutin K63R were from Dr. M. Eilers. Flag-HA-USP1, Flag-HA-USP3,
Flag-HA-USP5, Flag-HA-USP8, Flag-HA-USP10, Flag-HA-USP21, FlagHA-USP26, were described previously (121). Myc-USP7 was obtained
from Dr. Pier Paolo Pandolfi (108). Flag-USP22 was obtained from Dr.
Didier Devys. Flag-CYLD and Flag-CYLD-C/A (C601A) were obtained
from Dr. Xin. Lin.
(From Science, 25 (5944): 1134-1138 (2009) and Science Signaling, 6
(257), ra3. (2013). Reprinted with permission from AAAS.)

2-4. Sited- directed mutagenesis of Akt
pcDNA6-HA-Akt1 K8R, pcDNA6-HA-Akt1 K14R, pcDNA6-HA-Akt1 K20R,
pcDNA6-HAAkt1 K30R, pcDNA6-HA-Akt1 K39R, pcDNA6-HA-Akt1 K64R, pcDNA6HA-Akt1 E17K, and pcDNA6-HA-Akt1 K8R/E17K constructs were generated using a
site-directed mutagenesis kit (Stratagene) according to the manufacturer’s standard
procedures with pcDNA6-HA-Akt1 as the template.

2-5. Immunoprecipitation (IP), immunoblotting (IB) and immunofluorescence (IF)
assays
IP, IB and IF were performed essentially as described elsewhere (39, 139). For
protein-protein interactions, cells were lysed by E1A lysis buffer [250 mM NaCl, 50 mM
HEPES (pH 7.5), 0.1% NP- 40, 5 mM EDTA, protease inhibitor cocktail (Roche)].

2-6. GST pull-down assay
For in vitro TRAF6 and Akt1 interaction, GST, GST-TRAF6, and
GSTTRAF6 C70A proteins purified from the bacterial lysates of BL21
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competent cells transformed with pGEX-4X1, pGEX-4X1-TRAF6, and
pGEX-4X1-TRAF6 C70A using glutathione-agarose beads according to the
manufacturer’s standard procedures. The GST, GST-TRAF6, and GSTTRAF6 C70A proteins bound to glutathione Sepharose beads (Amersham
Biosciences) were then incubated with the in vitro translated [35S]-Akt1 for
4 h at 4°C in the interaction buffer [20 mM HEPES (pH 7.9), 150 mM KCl,
5 mM EDTA, 0.5 mM dithiothreitol (DTT), 0.1% (v/v) NP-40, 0.1% (w/v)
BSA, 1 mM PMSF, and 10% glycerol], washed with NETN buffer [20 mM
Tris (pH 8.0), 100 mM NaCl, 6 mM MgCl2, 1 mM EDTA, 0.5% Nonidet P40, 1 mM DTT, 8% glycerol, and 1 mM PMSF] 4 times, and subjected to 8%
sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE),
followed by autoradiography.
(From Science, 25 (5944): 1134-1138 (2009). Reprinted with permission
from AAAS.)

2-7. in vivo and in vitro ubiquitination assay
In vivo ubiquitination assays were performed as described elsewhere
(141). In brief, 293T cells were transfected with the indicated plasmids for
48 h and lysed by denatured buffer (6 M guanidine-HCl, 0.1 M
Na2HPO4/NaH2PO4, 10 mM imidazole), followed by nickel bead
purification and Immunoblot analysis. In vitro ubiquitination assays using
GST-TRAF6 and GSTAKT- Flag were performed as described elsewhere
(140). Purified GST-TRAF6 and GST-AKT-Flag were incubated for 3 h at
37°C in 20 µl of reaction buffer [20 mM Hepes (pH 7.4), 10 mM MgCl2, 1
mM DTT, 59 µM ubiquitin, 50 nM E1, 850 nM of Ubc13/UeV1a, 1 mM
ATP, 30 µM creatine phosphate, and 1 U of creatine kinase]. After
incubation, the beads were washed five times in Buffer A [20 mM Tris (pH
7.4), 250 mM NaCl, 1 mM DTT, 1 mM sodium orthovanadate, 2 mM
EDTA, and 1% Triton X-100] and two times in low-salt buffer [20 mM Tris
[pH 7.4], 25 mM NaCl, and 1 mM DTT]. Beads were then resuspended in 1%
SDS (in water) and boiled for 10 min. Dissociated proteins were diluted
with 2×600 µl Buffer A, and the supernatant fluid was precleared with
Protein A/G beads for 1 h, and immunoprecipitated overnight with 1 µg
anti-Flag antibody, after which Protein A/G beads were added for an
additional 1 h. Beads were washed 4 times with Buffer A and 2 times with
low-salt buffer. Proteins were eluted in SDS-sample buffer, subjected to
SDSPAGE, transferred to nitrocelluose membrane, and immunoblotted with
anti-ubiquitin.
(From Science, 25 (5944): 1134-1138 (2009). Reprinted with permission
from AAAS.)
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2-8. Endogenous ubiquitination assay
Cells were seeded in 100 mm2 dishes and were serum-starved for 24 hours in DMEM
containing 0.1% FBS. After starvation, cells were treated with/without 50 ng/ml IGF-1 for
15 min. Cells were lysed by RIPA lysis buffer [50 mM TrisHCl pH7.4, 150 mM NaCl, 2
mM EDTA, 1% NP-40, 0.1% SDS and protease inhibitor cocktail (Roche)] with 10 mM
N-Ethylmaleimide (Calbiochem). Immunoprecipitation was performed to pull-down
polyubiquitinated Akt proteins. Samples were subjected to SDS-PAGE and immunoblotted
with anti-ubiquitin antibody.

2-9. in vitro deubiquitination assay
To purify ubiquitinated Akt (Akt-Ub), HEK293T were transfected with
HA-Akt along with His-Ub. After 48 hours, the cells were lysed with RIPA
buffer (1% NP-40) and immunoprecipitated by anti-HA antibody. Purified
Akt-Ub was washed by RIPA buffer for 4 times. To purify CYLD
deubiquitinase, HEK293T were transfected with Flag-CYLD-WT or FlagCYLD-C/A for 48 hours and lysed with Flag lysis buffer. The cell extracts
were subjected to immunoprecipitation using anti-Flag antibody, followed
by Flag peptide elution. To perform in vitro ubiquitination assays, the
purified Akt-Ub was incubated with each purified CYLD-WT or CYLDC/A in a deubiquitination buffer (50 mM Tris-HCl [pH 8.0], 50 mM NaCl,
1 mM EDTA, 10 mM DTT and 5% glycerol) for 2 hours at 37°C. After
incubation, proteins on the beads were eluted in SDS-sample buffer,
subjected to SDS-PAGE, transferred to nitrocelluose membrane, and
immunoblotted with anti-Akt antibody.
(From Science Signaling, 6 (257), ra3. (2013). Reprinted with permission
from AAAS.)

2-10. Retroviral/lentiviral production and infection
For TRAF6 overexpression by retroviral infection, retroviral plasmid
PMX, PMX-TRAF6, and PMX-TRAF6 C70A were transfected into
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Phoenix packing cells for 2 days, and the virus-containing medium was
harvested and used to infect primary Traf6+/+ and Traf6–/– MEFs.
For TRAF6 expression knockdown by lentiviral short hairpin RNA
(shRNA) infection, 293T cells were cotransfected TRAF6 or GFP control
shRNA with packing plasmids (deltaVPR8.9) and envelope plasmid (VSVG) using Lipofectamine 2000 reagent according to the manufacturer’s
instructions.
TRAF6-lentivivral
shRNA-1
(5'GCCACGGGAAATATGTAATATCT-3'), TRAF6-lentivivral shRNA-2 (5'
CGAAGAGATAATGGATGCCAAC-3'),
control
shRNA
(5'GCAAGCTGACCCTGAAGTTC-3') were transfected with packing
plasmids into 293T cells for 2 days, and virus particles containing TRAF6
or control shRNAs were used to infect PC-3 cells. All the infected cells
were cultured in medium containing 2 µg/ml puromycin for 4 days.
For CYLD expression knockdown by lentiviral short hairpin RNA
(shRNA) infection, HEK293T cells were cotransfected control or CYLD
shRNA with packing plasmids (deltaVPR8.9) and envelope plasmid (VSVG) by using calcium phosphate precipitation technique. CYLD-lentivivral
shRNA #1 (5'- TACTTAGACTCAACCTTATTC-3'), CYLD-lentivivral
shRNA #2 (5' AAGAAGGTCGTGGTCAAGGTC-3'), control shRNA (5'GCAAGCTGACCCTGAAGTTC-3') were transfected with packing
plasmids into HEK293T cells for 2 days, and virus particles containing
CYLD or control shRNAs were used to infect PC-3, DU-145 and MDAMB-231 cells. All the infected cells were cultured in medium containing 2
µg/ml puromycin for selection up to 1 week.
(From Science, 25 (5944): 1134-1138 (2009) and Science Signaling, 6
(257), ra3. (2013). Reprinted with permission from AAAS.)

2-11. PIP3 phospholipid binding
293T cells transfected with WT HA-Akt and various HA-Akt mutants for 48 h were
lysed by E1A buffer, and the cell lysates were incubated with control beads or PIP3 beads
(Enchelon) overnight. The beads were washed four times with E1A buffer and subjected to
Immunoblot analysis.

2-12. Cell membrane fractionation assay
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Cells were seeded in 100 mm2 dishes and were serum-starved for 24 hours in DMEM
containing 0.1% FBS. After starvation, cells were treated with 50 ng/ml IGF-1 in indicated
times. Cytosolic and membrane fractions were prepared using the ProteoExtract kit
(Calbiochem) according to the manufacturers’ standard procedures.

2-13. Cell growth assay
Cyld+/+ and Cyld-/- MEFs (5× 103 cells), DU-145 or MDA-MB-231 cells with control
and CYLD knockdown (5× 103 cells), or PC-3 cells with control and CYLD knockdown
(2× 103 cells) were seeded in 12 wells plate in triplicate. Cells were harvested, stained with
trypan blue and counted viable cells every two days up to six days. Viable cells were
counted on hemocytometer directly under the phage-contrast microscope.

2-14. Cell apoptosis assay
Cell were seeded in 60 mm2 dishes in triplicate and were either serum-starved (0.1%
FBS) or cultured in 10% FBS for 2 days or treated with/without 50 µM Cisplatin for 24
hours. Cells were collected and labeled with Annexin V-FITC apoptosis detection kit (BD
Pharmingen) according to the manufacturers’ standard procedures, followed by flow
cytometry analysis.

2-15. Glucose uptake assay
Cells were seeded in 60 mm2 dishes in triplicate. After 24 hours, cells were refreshed
with 0.1% FBS and glucose-free DMEM for 24 hours serum-starvation. Cells treated
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with/without 50 ng/ml IGF-1 were grown in the presence of fluorescent glucose analog 2NBDG (50 µM; Invitrogen) for 1 hour (for PC-3 cells) and 24 hours (for MEFs),
respectively. 2-NBDG uptake ratio by cells was analyzed by FACS analysis.

2-16. in vivo tumorigenesis assay
PC-3 stable cells with control and TRAF6 or CYLD knockdown (2×106 cells) or DU145 stable cells with control and CYLD knockdown (5×106 cells) mixed with matrigel (1:1)
were subcutaneously injected into the left flank of 6-week-old athymic nude mice. Tumor
sizes of mice were measured weekly by using a caliper, and tumor volume was determined
by using the standard formula: L×W2×0.52, where L is the longest diameter and W is the
shortest diameter.

2-17. Assessing Akt kinase activity in vivo in mice tissues
Heart and skeletal tissues isolated from 2-week-old Traf6+/+ and Traf6–/– mice (n=5)
were lysed in RIPA buffer, and lysates were used to determine Akt activity using the Akt
kinase assay kit (Cell Signaling) according to the manufacturer’s standard procedures. For
IGF-1 injection, 2 week-old Traf6+/+ and Traf6–/– mice (n=4) were starved for 6 h and
intraperitoneally injected with IGF-1 (0.5 mg/kg) for various times. Skeletal and heart
muscles were then isolated for the in vitro Akt kinase assay.
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Chapter 3
The E3 ligase TRAF6 regulates Akt ubiquitination
and activation
Most of this work has been published in:
W-L Yang, J. Wang, C-H Chan, S-W Lee, A. D. Campos, B. Lamothe, L. Hur, B. C.
Grabiner, X. Lin, B. G. Darnay, H-K Lin. The E3 ligase TRAF6 regulates Akt
ubiquitination and activation. Science 325 (5944): 1134-1138 (2009)
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RATIONALE
Protein ubiquitination is a significant posttranslational modification that controls a
variety of biological functions (72, 142). Although ubiquitination often causes protein
degradation, a certain type of ubiquitination which is essential for non-proteolytic
functions has been discovered recently (72, 142). Ubiquitination through Lys48 (K48)linked ubiquitin chain normally promotes proteins for degradation, whereas ubiquitination
through Lys63 (K63)-linked ubiquitin chain has a crucial role in protein trafficking, DNA
damage response and signaling activation (72, 142). Akt plays a critical central modulator
of cell signaling pathways that regulate cell growth, cell survival, cell cycle progression
and cellular metabolism (1, 9). Current model suggests that membrane translocation of Akt
by growth-factor stimuli is a crucial step for Akt signaling activation. However, it is not
clear how Akt is recruited to the plasma membrane. Since some of important functions of
ubiquitination are to promote protein trafficking and signaling activation, in this study, I
hypothesized that Akt may undergo non-proteolytic ubiquitination and this type of
modification may facilitate member translocation of Akt to further promote
phosphorylation and activation of Akt.
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RESULTS
3-1. Akt is undergoing K63-linked ubiquitination and TRAF6 is E3 ligase for Akt
ubiquitination.
To test our hypothesis, first of all we determined whether Akt is ubiquitinated in cells.
We found that Akt was ubiquitinated in the absence of proteasome inhibitor MG132,
suggesting ubiquitination of Akt is not responsible for protein degradation (Fig. 3-1A). We
also demonstrated that ubiquitination occurred on Akt through K63-linked but not through
K48-linked polyubiquitination (Fig. 3-1B). In addition, we screened a panel of ubiquitin
E3 ligases for ubiquitination of Akt. Although Mdm2 E3 ligase associates with Akt (40, 41,
139), it failed to promote ubiquitination of Akt (Fig. 3-1C). Other E3 ligases which
promote K48-linked ubiquitination on the substrate, including c-IAP1, c-IAP2, Cbl-b, Itch,
Smurf2, and Fbw7, also failed to induce Akt ubiquitination (Fig. 3-1C). Interestingly,
overexpression of c-IAP1 and c-IAP2 reduced rather than promoted ubiquitination of Akt
(Fig. 3-1C).
Because our preliminary results shown that Akt underwent K63-linked ubiquitination,
we focused on TRAF6 and HectH9, two ubiquitin E3 ligases that catalyze K63-linked
ubiquitination of the substrate. TRAF6 has an important regulatory role in TLR/IL1-R
signal transduction pathway, and HectH9 is involved in the oncogenic activation of Myc,
respectively (80, 99, 140). Our results showed that TRAF6 but not HectH9 promoted
ubiquitination of Akt (Fig. 3-1D).
We tested whether kinase activity of Akt is required for ubiquitination of Akt by
TRAF6 by using its constitutively activated (Akt-CA) and Akt kinase-dead (Akt-KD)
mutants. The result showed that both Akt mutants can be ubiquitination by TRAF6,
40

suggesting activity of Akt was not required for TRAF6-mediated ubiquitination (Fig. 3-1E).
Next, we determined whether TRAF6 E3 ligase activity is required for ubiquitination of
Akt. We found that the TRAF6 Cys70→Ala70 [C70A] mutant, which loses E3 ligase
activity (140), had compromised activity for ubiquitination of Akt (Fig. 3-1F). However,
this effect was not due to deficiency of interaction between TRAF6 mutant and Akt (Fig.
3-1G). Although TRAF6 promoted ubiquitination of Akt, it did not decrease the abundance
of Akt in cells (Fig. 3-1D and 3-1F), suggesting that TRAF6 does not mediate K48-linked
ubiquitination on Akt. Certainly, TRAF6 induced K63-linked but not K48-linked
ubiquitination of Akt (Fig. 3-1H). To further confirm previous results, we conducted in
vitro ubiquitination assay of Akt. The result showed that TRAF6, but not its C70A mutant,
induced Akt ubiquitination in vitro (Fig. 3-1I). Therefore, these results suggest that TRAF6
is an E3 ubiquitin ligase of Akt.
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A

B

Figure 3-1. TRAF6 is an E3 ubiquitin ligase for Akt.
(A) Immunoblot (IB) of lysed 293T cells, transfected with hemagglutinin (HA)-Akt
(HA)
and
His-ubiquitin (His-Ub)
Ub) constructs for 48 h. Ni
Ni–nitrilotriacetic
nitrilotriacetic acid (NTA) indicates nickel
bead precipitate.
T cells transfected with Akt along with His
His-Ub-WT,
WT, His–Ub
His
K48R, or
(B) IB of lysed 293T
His–Ub
Ub K63R constructs. WT indicates wild type; WCE, whole
whole-cell
cell extracts.
(Adapted from Science, 25 (5944): 1134
1134-1138 (2009).. Reprinted with permission from
AAAS.)
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C

D

Figure 3-1.
1. TRAF6 is an E3 ubiquitin ligase for Akt.
(C) IB of lysed 293T cells transfected with HA
HA-Akt, His-Ub,
Ub, along with various E3 ligases
for Akt E3 ligase candidate screening.
(D) IB of lysed 293T cells transfected with HA
HA-Akt and His-Ub,, along with HectH9 or
TRAF6 E3 ligases.
(Adapted from Science, 25 (5944): 1134
1134-1138 (2009).. Reprinted with permission from
AAAS.)
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F

E

G

1. TRAF6 is an E3 ubiquitin ligase for Akt.
Figure 3-1.
(E) 293T cells transfected with His
His-Ub
Ub and TRAF6, along with the constitutively active
Akt (HA-Akt
Akt CA) or kinase dead Akt (HA
(HA-Akt
Akt KD), were lysed for in vivo ubiquitination.
(F) IB of lysed 293T cells transfected with HA
HA-Akt and His-Ub,
Ub, along with TRAF6 or
TRAF6 C70A.
(G) 293T cells were transfected
nsfected with HA
HA-Akt and Flag-TRAF6 or Flag-TRAF6
TRAF6 C70A as
indicated for 48 h and lysed for immunoprecipitation (IP) with Flag antibody, followed by
immunoblot analysis.
(Adapted from Science, 25 (5944): 1134
1134-1138 (2009).. Reprinted with permission from
AAAS.)
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H

I

1. TRAF6 is an E3 ubiquitin ligase for Akt.
Figure 3-1.
(H) IB of lysed 293T cells transfected with Akt and TRAF6, along with HA–Ub
HA
K48
(K48-only ubiquitin) or HA––Ub K63 (K63-only
only ubiquitin). IP, immunoprecipitation.
(I) GST-Akt-Flag
Flag proteins were incubated with adenosine triphosphate, E1, and E2 along
with GST, GST-TRAF6,
TRAF6, or GST
GST–TRAF6
TRAF6 C70A proteins for in vitro ubiquitination of Akt.
(Adapted from Science, 25 (5944): 1134
1134-1138 (2009).. Reprinted with permission from
AAAS.)
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3-2. TRAF6 directly associates with Akt and its isoforms.
Our previous co-immunoprecipitation experiments showed that Akt associates with
overexpressed TRAF6 and with TRAF6 C70A mutant (Fig. 3-1G). In addition, we
detected the association between endogenous Akt and TRAF6 in cells stimulated with
IGF-1 growth factor or IL-1β cytokine (Fig. 3-2A), both of which activate Akt signaling
pathway. To further confirm previous results, we conducted in vitro protein binding assay.
We found that glutathione S-transferase (GST)–tagged recombinant TRAF6 interacted
with recombinant Akt directly in vitro (Fig. 3-2B). Since Akt has three isoforms, Akt1,
Akt2 and Akt3, we next examined whether TRAF6 can promote ubiquitination on these
Akt isoforms. Our result showed that ubiquitination of the Akt1 and Akt2 isoforms, but not
that of Akt3, was induced by TRAF6 (Fig. 3-2C). However, co-immunoprecipitation assay
showed that TRAF6 associated with all Akt isoforms (Fig. 3-2D).
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A

B

Figure 3-2. TRAF6 directly interacts with Akt in vivo and in vitro.
(A) MEFs cells were serum
serum-starved
starved for 1 day and treated with 100 ng/ml IGF-1
IGF or 20
ng/ml IL-1β for 30 min, and total cell lysates were immunoprecipitated with Akt antibody,
followed by Immunoblot ana
analysis.
(B) GST-TRAF6
TRAF6 C70A was incubated with in vitro translated [S35]-Akt,
Akt, washed, and
subjected to SDS-PAGE,
PAGE, followed by autoradiography.
(Adapted from Science, 25 (5944): 1134
1134-1138 (2009).. Reprinted with permission from
AAAS.)
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C

D

2. TRAF6 directly interacts with Akt in vivo and in vitro..
Figure 3-2.
(C, D) 293T cells transfected with indicated plasmids and harvested for in vivo
ubiquitination (C) and co-immunoprecipitation
immunoprecipitation (D) assays.
(Adapted from Science, 25 (5944): 1134
1134-1138 (2009).. Reprinted with permission from
AAAS.)
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3-3. TRAF6 promotes phosphorylation of Akt through ubiquitination of Akt.
We next examined the function of Akt ubiquitination induced by TRAF6. Our data
revealed that overexpression of TRAF6, but not that of TRAF6 C70A mutant, enhanced
phosphorylation of Akt at Thr308 but not at Ser473. This enhancement was correlated with
increased Akt kinase activity toward its substrate glycogen synthase kinase 3β (GSK3β)
(Fig. 3-3A) (10, 11), whereas a control HectH9 E3 ligase failed to promote
phosphorylation of Akt (Fig. 3-3B). In addition, overexpression of c-IAP1 and c-IAP2,
which slightly inhibited ubiquitination of Akt, reduced phosphorylation of Akt on Thr308
(Fig. 3-3C). These results suggest that TRAF6 may increase phosphorylation of Akt by
promoting ubiquitination of Akt.
Next, we tested whether TRAF6 is required for ubiquitination and phosphorylation of
Akt. To this end, we compared ubiquitination and phosphorylation of Akt in Traf6+/+ and
Traf6–/– primary mouse embryonic fibroblasts (MEFs) treated with inducers for Akt
activation. Upon stimulation with IGF-1, endogenous ubiquitination of Akt was reduced in
Traf6–/– MEFs compared with that in Traf6+/+ MEFs (Fig. 3-3D). Similarly, ubiquitination
of Akt was enhanced by 10% fetal bovine serum (FBS) or IL-1β in Traf6+/+ MEFs but not
in Traf6–/– MEFs (Fig. 3-3E). Accordingly, phosphorylation of Akt at Thr308 and Ser473
after IGF-1 treatment was decreased in Traf6–/– MEFs compared with that in Traf6+/+
MEFs (Fig. 3-3F). This defect in phosphorylation of Akt in Traf6−/− MEFs was
accompanied with an impairment in phosphorylation of two Akt substrates, Foxo1 and
Foxo3a (11, 143). Therefore, these results suggest that TRAF6 plays a critical role in the
regulation of IGF-1-mediated ubiquitination and phosphorylation of Akt.
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Since our previous results showed that TRAF6 is essential for IGF-1-induced
ubiquitination and phosphorylation of Akt, we next determined whether TRAF6 is directly
involved in IGF-1-mediated Akt activation. We found that ubiquitination of TRAF6, which
represents TRAF6 E3 ligase activity, was also induced by IGF-1 stimulation in two
different cell lines (Fig. 3-3G). In addition, TRAF6 interacted with IGF-1 receptor (IGF1R) in serum-deprived conditions but disruption of this interaction was found after IGF-1
treatment (Fig. 3-3H). Therefore, our findings suggest that activated IGF-1 receptor by
IGF-1 stimulation may directly engage TRAF6 activation and further promote
ubiquitination and phosphorylation of Akt.
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A

C

B

3. TRAF6 is required for ubiquitination and phosphorylation of Akt.
Figure 3-3.
(A) WCE from293T cells transfected with indicated plasmids was collected for IB analysis.
(B) WCE from 293T cells transfected with vector, TRAF6, or HectH9 for 48 h were
collected for immunoblot analysis.
(C) 293T cells transfected with various plasmids were lysed for in vivo ubiquitination and
IB analysis.
1134-1138 (2009).. Reprinted with permission from
(Adapted from Science, 25 (5944): 1134
AAAS.)
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E

F

3. TRAF6 is required for ubiquitination and phosphorylation of Akt.
Figure 3-3.
(D, E) Traf6+/+ and Traf6–/–– MEFs were serum-starved
starved for 1 day and treated with/without
IGF-11 (A) or 10% FBS or 20 ng/ml IL
IL-1β (B) for 30 min; WCE were collected for
immunoprecipitation with Akt, followed by IB analysis.
(F) MEFs were serum-starved,
starved, treated with IGF
IGF-1
1 for various time points, and harvested
for IB analysis.
(Adapted from Science, 25 (5944): 1134
1134-1138 (2009). Reprinted with permission from
AAAS.)
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H

3. TRAF6 is required for ubiquitination and phosphorylation of Akt.
Figure 3-3.
(G, H) COS-1 and PC-33 cells were serum
serum-starved
starved for 1 day and treated with or without 100
ng/ml of IGF-1;
1; WCE were collected for immunoprecipitation with TRAF6, followed by
immunoblot analysis with anti
anti-ubiquitin antibody (G) or anti-IGF-1Rβ antibody (H).
(
(Adapted from Science, 25 (5944): 1134
1134-1138 (2009).. Reprinted with permission from
AAAS.)

53

3-4.

TLR4/IL-1R signaling cooperates with growth factor receptor signaling to

promote Akt activation
Phosphorylations of Akt at Thr308 and Ser473 were also decreased in Traf6–/– MEFs
treated with 10% FBS (Fig. 3-4A). In contrast, phosphorylations of extracellular signalregulated protein kinase (ERK1) and ERK2 were similar in wild-type and Traf6–/– MEFs
(Fig. 3-4A). These results suggest that TRAF6 selectively regulates activation of Akt.
The endotoxin LPS and cytokine IL-1 can activate the TLR4/IL-1R signal
transduction pathway (99). Because TRAF6 is a central modulator for TLR4/IL-1R signal
transduction pathway (99, 140), we examined whether LPS- or IL-1β-mediated
phosphorylation of Akt acts through TRAF6. LPS or IL-1β treatment promoted
phosphorylation of Akt at Thr308 in Traf6+/+ MEFs in the presence of 10% FBS. However,
this effect was inhibited in Traf6−/− MEFs (Fig. 3-4B and 3-4C). In serum-starved
condition (0.1% FBS), neither LPS nor IL-1β was sufficient to initiate phosphorylation of
Akt at either Thr308 or Ser473 in primary MEFs and IMR90 cell line (Fig. 3-4D). Thus,
these results suggest that LPS and IL-1β may require cooperation with growth-factor
receptor signaling to induce activation of Akt.
Reconstitution of TRAF6 expression in Traf6−/− MEFs rescued the deficiency of
phosphorylation of Akt in cells treated with IGF-1 or IL-1β, whereas reconstitution of
TRAF6 C70A mutant did not (Fig. 3-4E and Fig. 3-4F). Therefore, these results suggest
that TRAF6 is required for phosphorylation and activation of Akt through induction of Akt
ubiquitination.
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A

1R signaling collaborates with growth factor receptor signaling
Figure 3-4. TLR4/IL-1R
in regulating activation of Akt.
(A) Traf6+/+ and Traf6–/– MEFs were serum
serum-starved
starved for 1 day, treated with 10% FBS for
various time points, and harvested for immunoblot analysis.
(Adapted from Science, 25 (5944): 1134
1134-1138 (2009).. Reprinted with permission from
AAAS.)
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C

1R signaling collaborates with growth factor receptor signaling
Figure 3-4. TLR4/IL-1R
in regulating activation of Akt.
(B, C) Traf6+/+ and Traf6–/–– MEFs cultured in 10% FBS were treated with 10 µg/ml LPS
(B) or 20 ng/ml IL-1β (C) for various times as indicated and harvested for immunoblot
analysis.
(Adapted from Science, 25 (5944): 1134
1134-1138 (2009).. Reprinted with permission from
AAAS.)
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D

Primary MEFs

IMR90

1R signaling collaborates with growth factor receptor signaling
Figure 3-4. TLR4/IL-1R
in regulating activation of Akt.
(D) Primary MEFs or IMR90 cell lines were serum
serum-starved
starved for 1 day, treated with 10%
FBS, 100 ng/ml IGF-1,
1, 10 µ
µg/ml LPS, or 20 ng/ml IL-1β in the absence of 10% FBS for
various times as indicated and harvested for IB analysis.
(Adapted from Science, 25 (5944): 1134
1134-1138 (2009).. Reprinted with permission from
AAAS.)
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F

1R signaling collaborates with growth factor receptor signaling
Figure 3-4. TLR4/IL-1R
in regulating activation of Akt.
(E, F) Primary Traf6–/– MEFs infected with mock, TRAF6, or TRAF6 C70A mutant were
treated with 100 ng/ml IGF
IGF-1 (E) or 20 ng/ml IL-1β (F) at various time points and
harvested for IB analysis.
(Adapted from Science, 25 (5944): 1134
1134-1138 (2009). Reprinted with permission from
AAAS.)
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3-5. TRAF6 regulates cell survival through activating Akt
Since Akt signaling activation controls cell survival and apoptosis (11, 143), we
determined whether Traf6 deficiency sensitized cells to apoptosis after serum withdrawal.
Our result demonstrated that apoptosis in Traf6–/– MEFs was higher than in Traf6+/+ MEFs
in the presence and absence of serum (Fig. 3-5A). Furthermore, the active, cleaved form of
caspase-3 which is a critical regulator of apoptosis, was more abundant in Traf6–/– MEFs
than in Traf6+/+ MEFs (Fig. 3-5B). In addition, reconstitution of TRAF6, but not TRAF6
C70A mutant, prevented Traf6−/− MEFs from apoptosis (Fig. 3-5C). However, a
constitutively active form of Akt (myristoylated Akt) partially prevented cells from
apoptosis (Fig. 3-5C), suggesting that other signaling pathways may be also engaged in the
cell survival response.
Since

apoptosis

inducers,

including

DNA

damage

agents,

also

promote

phosphorylation and activation of Akt (144, 145), we examined whether TRAF6 was also
involved in this process. Doxorubicin (Dox)- or cisplatin (Cis)-mediated phosphorylation
of Akt at Thr308 in wild-type MEFs was reduced in Traf6−/− MEFs (Fig. 3-5D). The
deficiency of phosphorylation of Akt was accompanied with increased activation of
caspase-3 in Traf6−/− MEFs (Fig. 3-5E). Accordingly, these results suggest that TRAF6
promotes activation of Akt in response to serum starvation- or DNA damage agentsinduced apoptosis.
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A

5. TRAF6 is required for Akt
Akt-mediated
mediated cell survival in response to serumserum
Figure 3-5.
starvation and DNA damage.
(A) MEFs were cultured in 10% FBS or serum
serum-starved
starved for 2 days, and apoptosis was
determined by annexin V staining, followed by flow cytometry analysis. Results are
presented as mean values ± SD.
(Adapted from Science, 25 (5944): 1134
1134-1138 (2009). Reprinted with permission from
AAAS.)
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B

C

5. TRAF6 is required for Akt
Akt-mediated
mediated cell survival in response to serumserum
Figure 3-5.
starvation and DNA damage.
(B) MEFs were serum-staved
staved for various times and harvested for IB analysis.
(C) MEFs were infected with mock, constitutively active Akt (Mri
(Mri-Akt),
Akt), TRAF6, or
TRAF6 C70A; and apoptosis and IB analysis were determined. Results are presented as
mean values ± SD.
1134-1138 (2009).. Reprinted with permission from
(Adapted from Science, 25 (5944): 1134
AAAS.)
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E

5. TRAF6 is required for Akt
Akt-mediated
mediated cell survival in response to serumserum
Figure 3-5.
starvation and DNA damage.
(D, E) Traf6+/+ and Traf6––/– MEFs were treated with Doxorubicin (Dox) and Cisplatin
(Cis) for various times and harvested for immunoblot analysis.
(Adapted from Science, 25 (5944): 1134
1134-1138 (2009).. Reprinted with permission from
AAAS.)
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3-6. TRAF6 regulates steady-state Akt activity in vivo.
Next, we used TRAF6 deficiency mouse model to further corroborate our previous
findings of the role of TRAF6 in regulating Akt activation in in vivo. TRAF6 is expressed
in most mouse tissues, such as skeletal muscle, heart and kidney (146, 147). We compared
Akt activity in skeletal muscle and heart tissues obtained from wild-type and Traf6−/− mice,
respectively. The result showed that steady-state Akt activity level in heart muscle, but not
skeletal muscle, was lower in Traf6−/− mice than in wild-type mice (Fig. 3-6A). In addition,
activation of Akt in animals injected with IGF-1 was reduced in both forms of muscles in
Traf6−/− mice (Fig. 3-6B). Therefore, these results suggest that TRAF6 plays a critical role
in Akt activation in vivo.
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A

6. TRAF6 is required for both steady
steady-state and IGF-1
1-induced Akt
Figure 3-6.
activation in vivo.
(A) Heart and skeletal muscle isolated from Traf6+/+ and Traf6–/– mice (n=5) was lysed
and subjected to an in vitro Akt kinase assay and immunoblot analysis. The graph (lower
panel) represents the averaged Akt activity from total 5 mice. Results are presented as
mean values ± S.D. *p<0.05
p<0.05, using Student’s t-test.
(Adapted from Science, 25 (5944): 1134
1134-1138 (2009).. Reprinted with permission from
AAAS.)
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B

6. TRAF6 is required for both steady
steady-state and IGF-1
1-induced Akt
Figure 3-6.
activation in vivo.
(B) Heart and skeletal muscles isolated from Traf6+/+ and Traf6–/– mice (n = 4) injected
with IGF-11 at various time points were subjected to an in vitro Akt kinase assay and IB
analysis.
(Adapted from Science, 25 (5944): 1134
1134-1138 (2009).. Reprinted with permission from
AAAS.)
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3-7. TRAF6 ubiquitinates Akt at the PH domain of Akt.
Because the pleckstrin homology (PH) domain of Akt is critical for
PIP3 phospholipid binding and protein-protein interaction (10, 148), we
analyzed whether the PH domain of Akt influenced TRAF6-mediated
ubiquitination of Akt. Indeed, TRAF6 failed to promote ubiquitination of
the Akt mutant devoid of the PH domain (Fig. 3-7A). Of the six lysine
residues (K8, K14, K20, K30, K39, K64) within the PH domain of Akt,
mutation on either K8 or K14 to arginine (R) most substantially reduced
Akt ubiquitination and Akt phosphorylation at Thr308 and Ser473 (Fig. 3-7B).
In addition, amino acid sequence alignment and analysis for the PH domain
of Akt revealed that the K8 and K14 residues are well conserved from
Drosophila to humans (Fig. 3-7C), suggesting that the ubiquitination site of
Akt may be evolutionarily conserved.
Next we tested whether ubiquitination within the PH domain of Akt
affects Akt interaction with PIP3. The result of PIP3 binding assay showed
that Akt K8R mutant bound effectively to isolate PIP3, but Akt K14R
mutant did not (Fig. 3-7D). The K14 residue lies within the PIP3
phospholipid-binding pocket (21, 56, 149). In addition, overexpression of
TRAF6 did not enhance the binding of Akt to PIP3 (Fig. 3-7D). Thus, Akt
ubiquitination by TRAF6 appears not to influence PIP3 lipid binding, and
the defect in phosphorylation of Akt K8R mutant is not due to its
impairment in PIP3 binding.
A mutation in the PH domain [Glu17→Lys17, E17K] of Akt has been
identified in human cancer patients, including those with breast and colon
cancers (56). This cancer-associated Akt mutant exhibited constitutive Akt
phosphorylation at Thr308 but not at Ser473 and had greater oncogenic
potential. Since this mutant gains an additional lysine within the PH domain
of Akt, we inferred that this mutant may have higher ubiquitination level,
leading to hyper-activation of this mutant. To test this hypothesis, we next
examined ubiquitination of Akt E17K mutant compared with Akt wild-type.
The result showed that basal ubiquitination of the E17K mutant was much
higher than that of wild-type Akt (Fig. 3-7E). In addition, overexpression of
TRAF6 still increased ubiquitination of this mutant but to a lesser extent
than wild-type Akt (Fig. 3-7E). The E17K mutant displayed higher Akt
phosphorylation at Thr308 but not at Ser473 (56), however this was not
increased by TRAF6 overexpression (Fig. 3-7E). To further confirm the
role of ubiquitination in Akt E17K mutant, we generated and tested the Akt
K8R/E17K mutant. The result supported our previous findings that
ubiquitination of a K8R/E17K Akt mutant in vivo was reduced and
correlated with a reduction in phosphorylation of Akt Thr308 (Fig. 3-7F).
Thus, increased Akt ubiquitination apparently contributes to the hyperactivation of Akt observed in the Akt E17K mutant.
(From Science, 25 (5944): 1134-1138 (2009). Reprinted with permission
from AAAS.)
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7. The PH domain of Akt is required for Akt ubiquitination by TRAF6.
Figure 3-7.
(A) IB of lysed 293T cells transfected with His
His-Ub along with HA-Akt
Akt or HA–Akt
HA
∆PH.
(B) IB of 293T cells transfected with His
His-Ub along with HA-Akt
Akt or various HA-Akt
HA
mutants and lysed for ubiquitination and phosphorylation of Akt.
(Adapted from Science, 25 (5944): 1134
1134-1138 (2009).. Reprinted with permission from
AAAS.)
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7. The PH domain of Akt is required for Akt ubiquitination by TRAF6.
Figure 3-7.
(C) Conservation of the K8 and K14 residues within the PH domain of Akt among the
species.
(D) WCE from 293T cells transfected with HA
HA-Akt
Akt or various Akt mutants were incubated
with control or PIP3 beads for overnight, washed, and subjected to IB analysis. The PIP3
binding was calculated as the ratio between amounts of Akt bound with PIP3 beads and
total amounts of Akt.
(Adapted from Science, 25 (5944): 1134
1134-1138 (2009).. Reprinted with permission from
AAAS.)
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7. The PH domain of Akt is required for Akt ubiquitination by TRAF6.
Figure 3-7.
(E) IBs of lysed 293T cells transfected with TRAF6, His
His-Ub, HA-Akt
Akt WT or E17K mutant.
(F) IBs of lysed 293T cells transfected with His
His-Ub, HA-Akt
Akt WT, E17K or K8R/E17K
mutant.
(Adapted from Science, 25 (5944): 1134
1134-1138 (2009).. Reprinted with permission from
AAAS.)
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3-8. TRAF6-mediated ubiquitination of Akt promotes recruitment of Akt to the
plasma membrane.
Because K63-linked ubiquitination regulates protein trafficking among
different cellular compartments, we tested whether TRAF6 influenced
membrane recruitment of Akt. Indeed, overexpression of TRAF6 increased
Akt membrane localization, which correlated with an increase in
phosphorylation and ubiquitination of Akt (Fig. 3-8A). In addition, IGF-1induced membrane localization and phosphorylation of Akt at Thr308 in
wild-type MEFs was abolished in Traf6–/– MEFs (Fig. 3-8B). Thus, TRAF6
is required for Akt membrane recruitment and phosphorylation upon IGF-1
stimulation.
We also compared the membrane recruitment of wild-type Akt and Akt
mutants (K8R, K14R, E17K and K8R/E17K), which affects Akt
ubiquitination. The result showed that membrane recruitment of Akt K8R
and K14R upon IGF-1 treatment was reduced (Fig. 3-8C). Furthermore, the
Akt E17K mutant localized to the membrane, even without IGF-1
stimulation, although IGF-1 stimulation further increased membrane
recruitment (Fig. 3-8C). In contrast, the Akt K8R/E17K mutant showed
impaired association with the membrane (Fig. 3-8C). Accordingly, this
result suggests that Akt ubiquitination contributes to membrane recruitment
and phosphorylation of Akt.
(From Science, 25 (5944): 1134-1138 (2009). Reprinted with permission
from AAAS.)
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8. Ubiquitination of Akt is required for membrane recruitment of Akt.
Figure 3-8.
(A) The membrane (Mem) and cytosolic (Cyto
(Cyto)) fractions from 293T cells transfected with
mock or TRAF6 were subjected to IB analysis.
(B) MEFs were serum-starved
starved and treated with IGF
IGF-1,
1, and the membrane and cytosolic
fractions were isolated for IB analysis.
(Adapted from Science, 25 (5944): 1134
1134-1138 (2009).. Reprinted with permission from
AAAS.)
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8. Ubiquitination of Akt is required for membrane recruitment of Akt.
Figure 3-8.
(C) COS-11 cells were transfected with indicated plasmids, serum
serum-starved,
starved, and treated with
IGF-1 for 15 min; and the cytosolic (Cyto) and membrane (Mem) fractions were isolated
for IB analysis.
(Adapted from Science, 25 (5944): 1134
1134-1138 (2009).. Reprinted with permission from
AAAS.)
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8. Ubiquitination of Akt is required for membrane recruitment of Akt.
Figure 3-8.
(D) NIH3T3 cells transfected with HA
HA-Akt
Akt or various Akt mutants for 24 h were serumserum
starved with 0.1% FBS for 1day, treated with 100 ng/ml of IGF
IGF-1
1 for 15 min, and fixed for
immunofluorescence. The Arrow indicates the membrane localization of Akt. The scale
bar represents 10 µm.
m. Quantification of the experiments is shown in lower panel. Results
are presented as mean values ± S.D. *p<0.05, **p<0.001 using Student’s tt-test.
test.
(Adapted from Science, 25 (5944): 1134
1134-1138 (2009). Reprinted
inted with permission from
AAAS.)
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3-9. TRAF6 is required for prostate cancer development.
Since deregulated Akt activity can contribute to human cancer development (9, 12),
we depleted TRAF6 protein expression in PC-3 prostate cancer cells by using short hairpin
RNAs (shRNAs) to determine whether TRAF6 is also involved in tumorigenesis through
regulating Akt activation. TRAF6 deficiency in PC-3 cells decreased phosphorylation of
Akt at Thr308 and Ser473 (Fig. 3-9A). Furthermore, in cells treated with IGF-1,
phosphorylation of Akt in TRAF6 deficient cells was impaired (Fig. 3-9B). In addition, in
xenograft tumor models, the two stable TRAF6 deficient cells showed lower tumorigenic
potential than control cells (Fig. 3-9C). Thus, these results suggest that TRAF6 appears to
influence tumorigenesis in this model probably through regulating ubiquitination and
activation of an oncogenic protein Akt.
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B

9. TRAF6 silencing inhibits tumorigenic potential of prostate cancer cells.
Figure 3-9.
(A, B) PC-33 cells silenced with control or TRAF6 shRNAs were harvested for IB analysis
or serum-starved,
starved, treated with IGF
IGF-1
1 for various times, and harvested for IB analysis.
(Adapted from Science, 25 (5944): 1134
1134-1138 (2009).. Reprinted with permission from
fro
AAAS.)
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9. TRAF6 silencing inhibits tumorigenic potential of prostate cancer cells.
Figure 3-9.
(C) PC-33 cells silenced with control or TRAF6 shRNAs were injected into nude mice (n =
6 for each group) and monitored for tumorigenesis. Results are presented as mean values ±
SD. *P < 0.05, using Student’s t test.
(Adapted from Science, 25 (5944): 1134
1134-1138 (2009).. Reprinted with permission from
AAAS.)
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SUMMARY
In this study, we have several important discoveries. First, we have demonstrated that
Akt can be conjugated with non-proteolytic K63-linked ubiquitination, and we have
identified that TRAF6 as an ubiquitin E3 ligase for Akt ubiquitination. Second, we have
determined that this novel modification on Akt is important for Akt membrane recruitment,
phosphorylation and activation upon stimulation with growth factor signaling. Third, we
have connected K63-linked ubiquitination of Akt to human cancer development by
examining a human cancer-associated Akt E17K mutant which exhibited high level of
ubiquitination correlated with its hyper-activation. Fourth, we also demonstrated that
TRAF6 is essential for prostate cancer development. Our results expand the known
functions of TRAF6 to include the PI3K/Akt oncogenic signaling pathways. Therefore, we
suggest that TRAF6 may be a previously uncharacterized oncogene that may serve as an
important therapeutic target for human cancers.
Based on our previous findings, we propose a hypothetical model as shown in Figure
3-10. First of all, IGF-1 receptor signaling induces activation of TRAF6 E3 ligase. In
addition, LPS- or IL-1-mediated TLR/IL-1R signaling pathway promotes Akt activation
through activating TRAF6, too. TRAF6 directly binds to inactive Akt in cytosol and
promotes K63-linked ubiquitination of Akt. This novel modification promotes membrane
recruitment, phosphorylation and activation of Akt. Activated Akt kinase promotes cell
proliferation, survival and metabolism and may further induce tumorigenesis. Our findings
suggest that K63-linked ubiquitination plays a crucial role in regulating activation of Akt
by promoting Akt membrane recruitment, and it also involved in oncogenic Akt
functionality and human cancer development.
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10. The working model for Akt activation.
Figure 3-10.
IGF-11 engagement to its membrane receptor, IGF
IGF-1R,
1R, and induces TRAF6 activation.
Activated TRAF6 then triggers ubiquitination of Akt, which is prerequisite to membrane
recruitment of Akt, where Akt can be anchored in the membrane by binding to the PIP3,
followed by phosphorylation of Akt at Thr308 and Ser473 induced by PDK1 and mTOR
complex 2 (mTORC2), respectively.
(This figure was adapted from our published work in Science, 25 (5944): 1134-1138
1134
(2009);; the permission was received from the journal.)
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Chapter 4
Cycles of Ubiquitination and Deubiquitination Critically Regulate
Growth Factor-mediated Activation of Akt Signaling
Most of this work has been published in:
W-L Yang, G. Jin, C-F Li, Y. S. Jeong, A. Moten, D. Xu, Z. Feng, W. Chen, Z. Cai, B.
Darnay, W. Gu and H-K Lin Cycles of Ubiquitination and Deubiquitination Critically
Regulate Growth Factor-mediated Activation of Akt Signaling. Science Signaling 6
(257), ra3. (2013)
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RATIONALE
In the first part of my thesis study, we have discovered that Akt undergoes K63-linked
ubiquitination by TRAF6 ubiquitin E3 ligase in response to growth factor or cytokine
signaling stimulation. Furthermore, we have demonstrated that K63-linked ubiquitination
is essential for membrane recruitment and phosphorylation of Akt and subsequent Akt
signaling activation. Importantly, we found that the regulation of Akt ubiquitination is
involved in human cancer development, suggesting that the regulation of Akt
ubiquitination may be a key factor to determine the tumorigenicity of Akt. However, one
outstanding question remains to be answered: how ubiquitination cycles of Akt are
regulated in response to distinct conditions such as serum deprivation and serum
stimulation. Here, we hypothesized that deubiquitinating enzymes (DUBs) in cells may
serve as molecular switches for this process by sensing the concentration of growth factor
in its microenvironment.
In this part of my study, the first step is to identify the DUB for deubiquitination of
Akt. Furthermore, we seek to understand how this specific DUB negatively regulates
growth factor-mediated membrane recruitment and activation of Akt through
deubiquitination of Akt. In addition, we also want to investigate the role of ubiquitination
and deubiquitination cycles in Akt
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RESULTS
4-1. CYLD is a DUB for deubiquitination of Akt
To understand the mechanism by which the Akt deubiquitination
process is regulated, we screened a panel of potential DUBs for Akt by
performing deubiquitination assays in cells ectopically expressing DUBs.
Among the DUBs, only CYLD effectively reduced the ubiquitination of Akt
(Fig. 4-1A). Because Akt has three isoforms (Akt1, Akt2, and Akt3), we
next examined whether CYLD displays differential specificity for various
Akt isoforms and found that CYLD promoted deubiquitination of Akt1 and
Akt2 (Fig. 4-1B).
CYLD inhibits activation of NF-κB and innate immune response (124,
128, 150). Mutation of the gene encoding CYLD is associated with some
inherited diseases such as familial cylindromatosis, which is characterized
by the development of tumors from skin appendages (cylindromatosis) (122,
124). Furthermore, loss of CYLD is found in various human cancers,
suggesting that CYLD may be a tumor suppressor (151). We found that the
inhibitory effect of CYLD on ubiquitination of Akt depended on its
catalytic activity because the catalytically dead mutant of CYLD (Cys601→
Ala601; C601A) failed to attenuate ubiquitination of Akt (Fig. 4-1C). CYLD
specifically removed K63-linked ubiquitination of Akt (Fig. 4-1D). Because
TRAF6 and Skp2 are E3 ligases for Akt and play critical roles in Akt
membrane recruitment, phosphorylation, and activation (152, 153), we
determined whether CYLD also regulates TRAF6- or Skp2-mediated
ubiquitination of Akt. Wild-type CYLD, but not its catalytic mutant,
inhibited both TRAF6- and Skp2-mediated Akt ubiquitination (Fig. 4-1C
and 4-1E). To determine whether CYLD is a direct DUB for Akt, we
performed in vitro deubiquitination assays and found that deubiquitination
of Akt was mediated by wild-type CYLD but not by the C601A mutant (Fig.
4-1F). These results suggest that CYLD is a bona fide DUB for Akt.
(From Science Signaling, 6 (257), ra3. (2013). Reprinted with permission
from AAAS.)
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A

Figure 4-1. CYLD deubiquitinase promotes deubiquitination of Akt.
(A) Cellular ubiquitination assays performed in HEK293T cells transfected with HisHis
ubiquitin (His-Ub),
Ub), hemagglutinin (HA)
(HA)–Akt,
Akt, along with various DUB constructs. Ni–
Ni
nitrilotriacetic acid (Ni-NTA),
NTA), nick
nickel bead precipitate; WCE, whole-cell
cell extracts.
(Adapted from Science Signaling, 6 (257), ra3. (2013). Reprinted with permission from
AAAS.)
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B

Figure 4-1. CYLD deubiquitinase promotes deubiquitination of Akt.
(B) HEK293T cells transfected with Flag-CYLD and His-Ub, along with HA-Akt1, HAAkt2 and HA-Akt3 isoforms were lysed for in vivo ubiquitination assay, followed by IB
analysis.
(Adapted from Science Signaling, 6 (257), ra3. (2013). Reprinted with permission from
AAAS.)
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1. CYLD deubiquitinase promotes deubiquitination of Akt.
Figure 4-1.
(C) Cellular ubiquitination assays performed in HEK293T cells transfected with HA-Akt,
HA
His-Ub, and Flag-TRAF6,
TRAF6, along with Flag
Flag-CYLD-WT or Flag-CYLD-C/A.
C/A. WT, wild type;
C/A, enzyme-dead
dead mutant (C601A).
(D) Immunoblot analysis of Akt immunoprecipitates from HEK293T cells transfected with
Akt and Flag-CYLD,
CYLD, along with HA
HA-Ub K48 (K48-only ubiquitin) or HA--Ub K63 (K63only ubiquitin). IB, immunoblot; IP, immunoprecipitation.
(Adapted from Science Signaling, 6 (257), ra3. (2013). Reprinted with permission from
AAAS.)
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1. CYLD deubiquitinase promotes deubiquitination of Akt.
Figure 4-1.
(E) Cellular ubiquitination assays performed in HEK293T cells transfected with HA-Akt,
His-Ub, and Xp-Skp2,
Skp2, along with Flag
Flag-CYLD-WT or Flag-CYLD-C/A.
(F) In vitro deubiquitination assays with purified ubiquitinated Akt proteins incubated with
purified Flag-CYLD-C/A
C/A or Flag
Flag-CYLD-WT proteins.
(Adapted from Science Signaling, 6 (257), ra3. (2013). Reprinted with permission from
AAAS.)
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4-2. CLYD interacts with Akt and its deficiency induces basal Akt ubiquitination.
We next determined whether CYLD deficiency promotes
ubiquitination of endogenous Akt in response to IGF-1 stimulation. In wildtype primary mouse embryonic fibroblasts (MEFs), endogenous Akt was
basally ubiquitinated under serum-starved conditions and ubiquitination was
increased by IGF-1, consistent with our previous report (Fig. 4-2A) (152).
Ubiquitination of endogenous Akt under serum-starved conditions in
Cyld−/− MEFs was similar to that seen in wild-type MEFs treated with IGF1, but was not further increased by IGF-1 treatment (Fig. 4-2A). Similarly,
prostate cancer cells lacking CYLD also displayed increased basal
ubiquitination of Akt in the absence of IGF-1 treatment (Fig. 4-2B). These
results suggest that CYLD keeps Akt in the hypoubiquitinated state and that
its deficiency facilitates ubiquitination of Akt.
We next determined whether Akt associates with CYLD. Coimmunoprecipitation assays showed that exogenously expressed Akt1
interacted with both wild-type and mutant CYLD (C601A) (Fig. 4-2C).
Likewise, exogenously expressed Akt2 and Akt3 also interacted with
CYLD (data not shown). Notably, phosphorylation of Akt at Thr308 and
Ser473, which indicate activation of Akt, was attenuated by wild-type CYLD
but not by C601A CYLD (Fig. 4-2C). Moreover, we found that endogenous
Akt interacted with CYLD under serum-starved conditions in a reciprocal
immunoprecipitation assay (Fig. 4-2D). The interaction between CYLD and
Akt was lost after 15 min of IGF-1 treatment (Fig. 4-2E), whereas the
interaction between Akt and TRAF6 was induced at the same time point
(152), suggesting that CYLD and TRAF6 may compete with each other for
Akt binding. Indeed, we found that TRAF6 overexpression inhibited the
binding of CYLD to Akt in a dose-dependent manner (Fig. 4-2F). These
results suggest that CYLD interacts with Akt under serum-starved
conditions and dissociates from Akt upon growth factor stimulation, which
may allow E3 ligases to bind to and ubiquitinate Akt.
(From Science Signaling, 6 (257), ra3. (2013). Reprinted with permission
from AAAS.)
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2. CYLD interacts with Akt and inhibits the ubiquitination of endogenous
Figure 4-2.
Akt.
(A) Immunoblot analysis of Akt immunoprecipitates from Cyld+/+ and Cyld−/− MEFs that
were serum starved and treated with or without IGF
IGF-1.
(B) Immunoblot analysis
nalysis of Akt immunoprecipitates from control or CYLD stable
knockdown PC-3 or DU-145
145 cells that were serum starved and treated with or without
IGF-1.
(Adapted from Science Signaling, 6 (257), ra3. (2013). Reprinted with permission from
AAAS.)
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2. CYLD interacts with Akt and inhibits the ubiquitination of endogenous
Figure 4-2.
Akt.
(C) Immunoblot analysis of HA immunoprecipitates from HEK293T cells transfected with
HA-Akt along with Flag-CYLD
CYLD-WT or Flag-CYLD-C/A.
(D) Immunoblot analysis
lysis of CYLD or Akt immunoprecipitates from serum-starved
serum
PC-3
cells. (B) PC-33 cells were serum
serum-starved and harvested for co-immunoprecipitation
immunoprecipitation assay
with CYLD or Akt antibody respectively, followed by IB analysis. Pull down % indicates
percentage of Akt or CYLD protein pulled down from total Akt or CYLD protein.
(Adapted from Science Signaling, 6 (257), ra3. (2013). Reprinted with permission from
AAAS.)
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Figure 4-2. CYLD interacts with Akt and inhibits the ubiquitination of endogenous
Akt.
(E) Immunoblot analysis of Akt immunoprecipitates from PC
PC-3
3 cells that were serumserum
starved and treated with IGF
IGF-1 at various time points.
(F) Immunoblot analysis of HA immunopreci
immunoprecipitates
pitates from HEK293T cells transfected with
HA-Akt along with Flag- CYLD or various amounts of Flag
Flag-TRAF6.
(Adapted from Science Signaling, 6 (257), ra3. (2013). Reprinted with permission from
AAAS.)
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4-3.

The interaction of Akt with CYLD is independent of its ubiquitination or

phosphorylation status
We next examined whether the ubiquitination status of Akt affects its
interaction with CYLD. CYLD bound to both non-ubiquitinated and
ubiquitinated Akt forms (Fig. 4-3A), and both wild-type Akt and the
ubiquitination-deficient K8R mutant (152) interacted with CYLD (Fig. 43B). Because IGF-1 disrupts the interaction between Akt and CYLD, we
also determined whether phosphorylation of Akt attenuated (or disrupted)
its interaction with CYLD. Both wild-type and the constitutively active Akt
mutant T308D/S473D (Akt-DD) interacted with CYLD (Fig. 4-3C),
suggesting that the phosphorylation of Akt does not affect Akt and CYLD
interaction. Consistent with this notion, the phosphorylation-defective Akt
mutant T308A/T450A/S473A (Akt-AAA) also bound to CYLD, and
overexpression of TRAF6 induced a dose-dependent decrease in the
interaction between CYLD and the Akt-AAA mutant (Fig. 4-3D). These
results suggest that the ubiquitination or phosphorylation status of Akt may
not be critical for its interaction with CYLD.
(From Science Signaling, 6 (257), ra3. (2013). Reprinted with permission
from AAAS.)
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Figure 4-3. Ubiquitination and phosphorylation status of Akt does not affect the
interaction of Akt with CYLD.
(A) Immunoblot analysis of Flag immunoprecipitates from HEK293T cells transfected
with Flag-CYLD, HA-Akt,
Akt, His
His-Ub, and TRAF6.
(B) Immunoblot analysis of HA immunoprecipitates from HEK293T cells transfected with
Flag-CYLD and His-Ub,
Ub, along with HA
HA-Akt-WT or HA-Akt K8R.
(Adapted from Science Signaling, 6 (257), ra3. (2013). Reprinted with permission from
AAAS.)
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Figure 4-3. Ubiquitination and phosphorylation status of Akt does not affect the
interaction of Akt with CYLD.
(A) HEK293T cells transfected with Flag
Flag-CYLD, along with HA-Akt-WT
WT or HA-Akt-DD
HA
(T308D/S473D) were harvested for immunoprecipitation with HA antibody, followed
foll
by
IB analysis.
(B) HEK293T cell transfected with Flag
Flag-CYLD and HA-Akt-AAA
AAA (T308A/T450A/
S473A), along with dose-dependent
dependent Flag
Flag-TRAF6
TRAF6 were harvested for immunoprecipitation
with HA antibody, followed by IB analysis.
(Adapted from Science Signaling, 6 (257), ra3. (2013). Reprinted with permission from
AAAS.)
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4-4. Ubiquitination and deubiquitination of Akt are independent of PI3K activity.
PI3K activity plays an important role in growth facto-induced
activation of Akt. To determine whether PI3Kis involved in ubiquitination
and deubiquitination of Akt, we performed cellular ubiquitination and
deubiquitination assays for endogenous Akt in the presence or absence of
the PI3K inhibitor LY294002. Inhibition of PI3K activity did not inhibit
IGF-1-induced ubiquitination and CYLD-mediated deubiquitination of Akt
(Fig. 4-4A and 4-4B).
We further determined whether polyubiquitination-mediated membrane
recruitment of Akt could lead to its activation without PI3K activity. To this
end, human embryonic kidney (HEK) 293T cells were cotransfected with
wild-type Akt, ubiquitination-deficient K8R Akt mutant, or cancerassociated E17K Akt mutant, which displays much higher ubiquitination of
Akt compared to wild-type Akt (152), in the presence or absence of
LY294002. Consistent with our previous observation (152), we found that
phosphorylation of Akt was increased in cells expressing the E17K mutant,
whereas those expressing the ubiquitination-deficient K8R mutant showed
reduced phosphorylation of Akt compared to wild-type Akt. However, PI3K
inhibition by LY294002 reduced phosphorylation of wild-type Akt and the
E17K and K8R mutants (Fig. 4-4C), suggesting that although
polyubiquitination of Akt is required for its phosphorylation and activation,
it is not sufficient to lead to Akt activation without PI3K activation.
(From Science Signaling, 6 (257), ra3. (2013). Reprinted with permission
from AAAS.)
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Figure 4-4. PI3K activity is not required for ubiquitination and deubiquitination of
Akt.
(A) Immunoblot analysis of HA immunoprecipitates from serum
serum-starved
starved PC-3
PC cells that
were pretreated with or without the PI3K inhibitor LY294002 and treated with or without
IGF-1.
(B) Cellular ubiquitination assays performed in HEK293T cells transfected with
wi HA-Akt,
His-Ub, and Flag-CYLD
CYLD and pretreated with or without LY294002.
(Adapted from Science Signaling, 6 (257), ra3. (2013). Reprinted with permission from
AAAS.)
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C

Figure 4-4. PI3K activity is not required for ubiquitination and deubiquitination of
Akt.
(C) Immunoblot analysis of HEK293T cells transfected with HA
HA-Akt-WT,
WT, HA-Akt-E17K,
HA
or HA-Akt-K8R
K8R and treated with or without LY294002.
(Adapted from Science Signaling, 6 (257), ra3. (2013). Reprinted with permission from
AAAS.)
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4-5. CYLD deficiency promotes membrane recruitment and phosphorylation of Akt.
The finding that CYLD interacts with Akt and suppresses
ubiquitination of Akt prompted us to determine whether CYLD prevents
phosphorylation of Akt in response to growth factor stimulation. Indeed,
Cyld−/− MEFs displayed higher basal phosphorylation of Akt (at 0 min) and
slightly enhanced IGF-1-mediated phosphorylation of Akt compared to
wild-type MEFs (Fig. 4-5A), which correlated with the increased basal
ubiquitination of Akt caused by Cyld deficiency (Fig. 4-2A). Likewise,
CYLD knockdown also promoted basal and IGF-1-and EGF-induced
phosphorylation of Akt in prostate cancer cell lines (Fig. 4-5B and 4-5C).
Conversely, restoration of wild-type CYLD, but not the C601A mutant, into
CYLD knockdown cancer cells reversed IGF-1-induced phosphorylation of
Akt, suggesting that the enzymatic activity of CYLD plays a critical role in
suppressing growth factor-induced phosphorylation of Akt (Fig. 4-5D).
Accordingly, our results suggest that CYLD opposes ubiquitination of Akt
and thereby inhibits its phosphorylation in response to stimulation with
growth factors.
We have shown that ubiquitination of Akt is critical for growth factormediated membrane recruitment and activation of Akt (152). Given that
CYLD opposes ubiquitination of Akt, it is possible that CYLD prevents
membrane recruitment of Akt, in turn inhibiting its phosphorylation and
activation. To test this hypothesis, we performed biochemical fractionation
experiments to determine whether CYLD regulates membrane recruitment
of Akt in the presence or absence of IGF-1 and EGF treatment. Consistent
with this notion, either Cyld deficiency or CYLD knockdown enhanced
basal membrane recruitment of Akt as well as basal and IGF-1- and EGFmediated phosphorylation of Akt in the plasma membrane (Fig. 4-5E, 4-5F
and 4-5G). Similar results were also obtained from immunofluorescence
analysis of wild-type and Cyld−/− MEFs (Fig. 4-5H). We next determined
whether PI3K activity is required for membrane translocation of Akt in
wild-type and Cyld−/− MEFs. PI3K inhibition efficiently blocked IGF-1induced membrane translocation of Akt in both wild-type and Cyld−/−MEFs
but failed to inhibit constitutive membrane recruitment of Akt in Cyld−/−
MEFs under serum-starved conditions (Fig. 4-5I). Thus, our results support
the notion that CYLD opposes Akt ubiquitination, in turn inhibiting growth
factor-mediated membrane recruitment and phosphorylation of Akt.
(Adapted from Science Signaling, 6 (257), ra3. (2013). Reprinted with
permission from AAAS.)
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A

5. CYLD deficiency facilitates growth factor
factor–mediated
mediated membrane
Figure 4-5.
recruitment and phosphorylation of Akt
Akt.
(A) Immunoblot analysis of Cyld+/+ and Cyld−/− MEFs that were serum-starved
starved and treated
with IGF-11 at various time points.
(Adapted from Science Signaling, 6 (257), ra3. (2013). Reprinted with permission from
AAAS.)
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5. CYLD deficiency facilitates growth factor–mediated
mediated membrane
Figure 4-5.
recruitment and phosphorylation of Akt
Akt.
(B) Immunoblot analysis of control or CYLD stable knockdown PC
PC-3
3 or DU-145
DU
cells that
were serum-starved
starved and treated with IGF
IGF-1 at various time points.
(C) Immunoblot analysis of control or two different CYLD-knockdown PC--3 cell lines that
were serum-starved
starved and treated with EGF at various time points.
(Adapted from Science Signaling, 6 (257), ra3. (2013). Reprinted with permission from
AAAS.)
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factor–mediated
mediated membrane
Figure 4-5. CYLD deficiency facilitates growth factor
recruitment and phosphorylation of Akt
Akt.
(D) Immunoblot analysis of CYLD
CYLD-knockdown PC-3
3 cells that were transfected with mock,
Flag-CYLD-WT, or Flag-CYLD
CYLD-C/A, serum-starved,
starved, and treated with IGF-1
IGF at various
time points.
(E) Immunoblot analysis of membrane and cytosolic fractions of Cyld+/+ and Cyld−/−MEFs
that were serum-starved
starved and treated with IGF
IGF-1 at various time points.
(Adapted from Science Signaling, 6 (257), ra3. (2013). Reprinted with permission
permis
from
AAAS.)
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5. CYLD deficiency facilitates growth factor
factor–mediated
mediated membrane
Figure 4-5.
recruitment and phosphorylation of Akt
Akt.
(F) Immunoblot analysis of membrane and cytosolic fractions of control or CYLD stable
knockdown PC-3 or DU-145
145 cells that were serum
serum-starved
starved and treated with IGF-1
IGF at
various time points.
(Adapted from Science Signaling, 6 (257), ra3. (2013). Reprinted with permission from
AAAS.)
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5. CYLD deficiency facilitates growth factor
factor–mediated
mediated membrane
m
Figure 4-5.
recruitment and phosphorylation of Akt.
(G) Immunoblot analysis of membrane and cytosolic fractions of control or two CYLDCYLD
knockdown PC-33 cell lines that were serum
serum-starved
starved and treated with EGF at various time
points.
(Adapted from Science Signali
Signaling, 6 (257), ra3. (2013). Reprinted with permission from
AAAS.)
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H

5. CYLD deficiency facilitates growth factor
factor–mediated
mediated membrane
Figure 4-5.
recruitment and phosphorylation of Akt.
(H) wild-type and Cyld-/- MEFs were serum
serum-starved,
starved, treated with/without IGF-1,
IGF and fixed
for immunofluorescence. The arrowhead indicates the membrane localization of Akt. The
scale bar represents 10 µm.
m. The quantification result is shown in lower panel. The results is
presented as mean percentage values from three biological replicates; N.S., non-significant
non
and ***P < 0.001 for all pairwise comparisons by Pearson chi
chi-square test.
(Adapted from Science Signaling, 6 (257), ra3. (2013). Reprinted with permission from
AAAS.)
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I
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Figure 4-5. CYLD deficiency facilitates growth factor–mediated membrane
recruitment and phosphorylation of Akt.
(I) Wild-type and Cyld-/- MEFs were serum-starved and pretreated with or without
LY294002 (LY). Then cells were treated with or without IGF-1 and fixed for
immunofluorescence. The arrowhead indicates the membrane localization of Akt. The
scale bar represents 10 µm. The quantification result is shown in lower panel. The result is
presented as mean percentage values from three biological replicates; N.S., non-significant
and *P < 0.05, ***P < 0.001 for all pairwise comparisons by Pearson chi-square test.
(Adapted from Science Signaling, 6 (257), ra3. (2013). Reprinted with permission from
AAAS.)
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4-6.

CYLD deficiency promotes cancer cell proliferation, cell survival, and

tumorigenesis.
Akt plays a crucial role in various biological processes, such as cell
proliferation, cell survival, and metabolism, and thus in tumorigenesis.
Because CYLD suppresses ubiquitination and activation of Akt, it is
possible that CYLD may also inhibit cancer cell proliferation and survival.
In support of this notion, we found that prostate cancer cells with CYLD
knockdown proliferated faster than control knockdown cancer cells (Fig. 46A). In addition, CYLD-deficient prostate cancer cells showed enhanced
cell survival in response to treatment with the apoptosis inducer cisplatin
(Fig. 4-6B).
To determine whether CYLD inhibits cell proliferation and survival by
suppressing activation of Akt, we performed cell proliferation and apoptosis
assays on control and CYLD-knockdown prostate cancer cells treated with
or without the PI3K inhibitors LY294002 or wortmannin. PI3K inhibitors
compromised the increase in cell proliferation and survival in CYLD
deficient prostate cancer cells, suggesting that CYLD inhibits these
biological events through the PI3K-Akt pathway (Fig. 4-6C and 4-6D).
However, because the PI3K inhibitors did not completely abolish the effect
of CYLD deficiency on cell proliferation and survival, we cannot exclude
the possibility that CYLD may also regulate other pathways. Because
CYLD inhibits NF-κB activation (122, 128, 150), it is probable that both
PI3K-Akt and NF-κB signaling pathways are involved in CYLD-regulated
cell proliferation and survival.
Akt promotes glucose uptake for glycolysis and adenosine triphosphate
production by inducing the plasma membrane localization of glucose
transporters, such as Glut1 and Glut4 (154-157). Because CYLD attenuates
activation of Akt, we hypothesized that CYLD may inhibit membrane
translocation of both Glut1 and Glut4 and glucose uptake. Indeed, we found
that Cyld−/− MEFs showed increased membrane localization of Glut1 and
Glut4 compared to wild-type MEFs (Fig. 4-6E). Although glucose uptake in
Cyld−/− MEFs was slightly higher than that in wild-type MEFs, this
difference was not statistically significant (Fig. 4-6F). However, CYLDknockdown prostate cancer cells displayed increased membrane localization
of Glut1, but not of Glut4, and higher glucose uptake compared to control
knockdown cells (Fig. 4-6E and 4-6F). Accordingly, these results suggest
that CYLD inhibits proliferation, survival, membrane translocation of Glut1,
and glucose uptake of prostate cancer cells.
(From Science Signaling, 6 (257), ra3. (2013). Reprinted with permission
from AAAS.)
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A

6. CYLD inhibits cancer cell proliferation, cell survival, and glucose uptake.
Figure 4-6.
(A) Cell proliferation in control or CYLD stable knockdown PC
PC-3
3 or DU-145
DU
cells,
presented as means ± SD from three biological replicates. **P < 0.01, ***P <0.001 for all
pairwise comparisons by one
one-way
way analysis of variance (ANOVA) and post hoc intergroup
comparisons with Sidak test.
(Adapted from Science Signaling, 6 (257), ra3. (2013). Reprinted with permission from
AAAS.)
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B

6. CYLD inhibits cancer cell proliferation, cell survival, and glucose uptake.
Figure 4-6.
(B) Cell apoptosis as determined by annexin V staining and flow cytometric analysis in
control or CYLD stable knockdown PC
PC-3 or DU-145
145 cells that were treated with vehicle or
cisplatin. Results are presented as mean percentages from three biological replicates.
replic
*P <
2
0.05, **P < 0.01 for all pairwise comparisons by Pearson χ test.
(Adapted from Science Signaling, 6 (257), ra3. (2013). Reprinted with permission from
AAAS.)
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C

6. CYLD inhibits cancer cell proliferation, cell survival, and glucose uptake.
Figure 4-6.
(C) Cell proliferation in control or CYLD
CYLD-knockdown PC-3 or DU-145
145 cells treated with
vehicle, LY294002 (LY), or wortmannin (Wort), presented as means ± SD from three
biological replicates. ***P < 0.001 for all pairwise comparisons by one
one-way
way ANOVA and
post hoc intergroup comparisons with Sidak test.
(Adapted from Science Signaling, 6 (257), ra3. (2013). Reprinted with permission from
AAAS.)
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D

6. CYLD inhibits cancer cell proliferation, cell survival, and glucose uptake.
Figure 4-6.
(D) Cell apoptosis as determined by annexin V staining and flow cytometric analysis in
control or CYLD stable knockdown PC
PC-3 or DU-145
145 cells that were pretreated with
vehicle, LY294002 (LY), or wortmannin (Wort), then with vehicle or cisplatin. Results are
presented as mean percentages from three biological replicates. *P < 0.05, **P < 0.01 for
all pairwise comparisons by Pearson χ2 test.
(Adapted from Science Signaling
Signaling, 6 (257), ra3. (2013). Reprinted with permission from
AAAS.)
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E

6. CYLD inhibits cancer cell proliferation, cell survival, and glucose uptake.
Figure 4-6.
(E) Immunoblot analysis ofGlut1 and Glut4 in cytosolic or membrane fractions of Cyld+/+
and Cyld−/− MEFs or PC-33 cells with control or CYLD knockdown that were treated with
IGF-11 for the indicated time intervals.
(Adapted from Science Signaling, 6 (257), ra3. (2013). Reprinted with permission from
AAAS.)
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F

6. CYLD inhibits cancer cell proliferation, cell survival, and glucose uptake.
Figure 4-6.
(F) Analysis of glucose uptake ratios in Cyld+/+ and Cyld−/− MEFs or PC-3
PC cells with
control or CYLD knockdown, treated with or without IGF
IGF-1
1 and grown in the presence of
the fluorescent glucose analog 22-NBDG.
NBDG. Results are presented as mean percentages from
three biological replicates. N.S., non
non-significant; ***P < 0.001
.001 for all pairwise
comparisons by Pearson χ22 test.
(Adapted from Science Signaling, 6 (257), ra3. (2013). Reprinted with permission from
AAAS.)
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4-7. CYLD serves as a tumor suppressive role in human prostate cancer development.
Loss of CYLD is found in melanoma, colon cancer, and liver cancer
(151). To determine whether CYLD also plays a tumor-suppressive role in
prostate cancer, we subcutaneously injected prostate cancer lines with
control or CYLD knockdown into athymic nude mice and monitored tumor
growth. We found that CYLD knockdown in two different prostate cancer
cell lines promoted prostate tumor growth (Fig. 4-7A). We next investigated
whether there was an inverse relationship between CYLD and Akt
activation in human prostate cancer samples. We retrospectively analyzed
representative tissue blocks of 80 primary prostate cancers in individuals
who underwent radical prostatectomy. Immunohistochemistry results
showed a significant negative correlation between phosphorylation of Akt at
Ser473 and CYLD abundance (Fig. 4-7B and 4-7C). In addition, compared to
early stage prostate cancer samples (stages I to IIA), advanced-stage
prostate cancer samples (stages IIB to III) displayed increased
phosphorylation of Akt at Ser473 and decreased CYLD abundance (Fig. 47D). These results suggest that CYLD suppresses Akt activation to inhibit
prostate cancer cell growth and development. Together, our results
underscore the role of CYLD in attenuating proliferation, glucose uptake,
and survival of cancer cells, and thus in tumor suppression.
(From Science Signaling, 6 (257), ra3. (2013). Reprinted with permission
from AAAS.)
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A

7. CYLD suppresses prostate cancer development.
Figure 4-7.
(A) PC-3 or DU-145
145 cells with control or CYLD knockdown were injected into nude mice
(n = 6 for each group), and the increase of tumor volume in mice was monitored every
week. Results are presented as means ± SD; *P < 0.05 for all pairwise comparisons by
one-way
way ANOVA and post hoc intergroup comparisons with Sidak test.
(Adapted from Science Signaling, 6 (257), ra3. (2013). Reprinted with permission from
AAAS.)
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B

Figure 4-7. CYLD suppresses prostate cancer development.
(B) Immunohistochemistry in representative primary non-metastatic prostate cancer
samples. A panel of images showing hematoxylin and eosin (H&E) staining, Akt
phosphorylated at Ser473, and CYLD staining in early- and advanced-stage prostate cancer
samples. Scale bar, 50 mm.
(Adapted from Science Signaling, 6 (257), ra3. (2013). Reprinted with permission from
AAAS.)
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C

D

7. CYLD suppresses prostate cancer development.
Figure 4-7.
(C) Histological score (H
(H-score) graph showing a negative correlation between
phosphorylation of Akt at Ser473 and CYLD abundance in prostate cancer samples. P <
0.001 by using Spearman’s correlation and Mann
Mann-Whitney U test.
(D) Associations of H-score
score between phosphorylation of Akt at Ser473 and CYLD
abundance
bundance and different tumor stages. Results are presented as means ± SD; P values were
obtained with Spearman’s correlation and Mann
Mann-Whitney U test.
(Adapted from Science Signaling, 6 (257), ra3. (2013). Reprinted with permission from
AAAS.)
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SUMMARY
The purpose of this study is to unveil the mechanism of ubiquitination cycle of Akt in
growth factor signaling pathway and in its role in regulating activation of Akt and
tumorigenesis. We have demonstrated that CYLD is a DUB for deubiquitination of Akt
and it inhibits growth factor–mediated Akt signaling activation. CYLD directly removes
K63-linked ubiquitination of Akt under serum-starved condition. Upon stimulation with
growth factor, CYLD disassociated with Akt thereby allowing E3 ligases for Akt to
promote ubiquitination and activation of Akt. In addition, CYLD deficiency promotes
cancer cell proliferation, survival, glucose metabolism and human prostate cancer
development. Therefore, our findings show the critical role of cycles of ubiquitination and
deubiquitination of Akt in regulating membrane translocation and activation of Akt, and
CYLD as a central switch for these processes.
Based on our previous findings, we propose a working model by which growth factor
signaling pathways regulate ubiquitination, membrane translocation and activation of Akt
(Fig. 4-8). CYLD associates with Akt and keeps Akt in a hypoubiquitinated and inactive
stage by directly removing Akt K63-linked ubiquitination under serum-starved condition.
However, stimulation with growth factors induce the disassociation of CYLD with Akt,
and this effect allows E3 ligases for Akt to bind to Akt and ubiquitinate Akt for subsequent
membrane recruitment and activation of Akt. Thus, our study suggests that CYLD serves
as a critical switch to orchestrate the ubiquitination and deubiquitination cycles of Akt,
thereby regulating membrane recruitment and activation of Akt, leading to tumorigenesis.
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8. The working model for growth factor
factor-mediated
mediated Akt ubiquitination and
Figure 4-8.
activation.
Under serum-starved
starved condition of the cell (left panel), CYLD interacts with inactive Akt
and keeps Akt in a hypoubiquitinated state. Upon stimulation with growth factors (right
panel), growth factor signaling may promote CYLD dissociating from Akt and allow
TRAF6 or Skp2 E3 ligase to interact with Akt and to elicit Akt ubiquitination, in turn
facilitating Akt membrane recruitment, phosphorylation and activation. Akt activation
therefore contributes to tumorigenesis by promoting cancer cells gro
growth,
wth, survival and
glucose metabolism.
(Adapted from Science Signaling, 6 (257), ra3. (2013). Reprinted with permission from
AAAS.)
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Chapter 5
Discussion
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5-1. Significance
My thesis study aims to understand and unveil the long-standing mystery in the
PI3K/Akt signaling field by investigating the molecular basis of growth factor signalmediated membrane recruitment and activation of Akt. We have made several significant
findings in the PI3K/Akt signaling field. We are the first to describe the molecular basis of
Akt membrane recruitment by non-proteolytic ubiquitination of Akt. Furthermore, we
identified TRAF6 as an E3 ligase for K63-linked ubiquitination of Akt. TRAF6 is a critical
signaling modulator in TLR/IL-1R signaling pathway. However, we unexpectedly found
that IGF-1 receptor signaling pathway promotes ubiquitination and activation of Akt
through activating TRAF6. Also, we have established the implication of K63-linked
ubiquitination of Akt in human cancer development. Thus, we proposed that TRAF6 may
have potential oncogenic function in regulation of tumorigenesis. In addition, we have
demonstrated the negatively regulatory mechanism for terminating ubiquitination and
activation of Akt. We identified a specific DUB, CYLD, capable of influencing the
activation of Akt through removing growth factor-mediated K63-linked ubiquitination of
Akt. Therefore, we have established a novel tumor suppressive model of CYLD through
suppressing Akt signaling, and expanded the essential tumor suppressive role of CYLD to
human prostate cancer.
Aberrant activation of Akt is well-known to be a common event associated with
human cancer development and progression (12, 66). However, how deregulation of Akt
signaling activation leads to tumor formation is still unclear. Although developing small
molecule inhibitors for targeting Akt in clinical trials are actively in progress, the results
are discouraging as direct targeting of this crucial signal molecule raised serious side
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effects such as diabetes and cardiac malfunctions (66). The failures of these inhibitors for
Akt suggest that more thorough understanding of Akt signaling activation mechanism is
required. Therefore, shedding light on the detailed mechanisms of activation and
tumorigenicity of Akt not only make a significant advance in cancer research, but also
provide the foundation to help the scientific community to develop innovative and
effective strategies for human cancer therapy with reducing side effects.
In summary, my thesis study establishes a novel model of ubiquitination cycle of Akt
in Akt signaling activation and human cancer development. This model may provide a new
paradigm for researches in cell biology, cancer biology and human cancer therapy in the
future.
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5-2. TRAF6 mediated K63-linked ubiquitination regulates activation of Akt.
Phosphorylation of Akt has an important role in activation and oncogenic functions of
Akt. In the past decade, the research involving Akt had been focused on the significance of
Akt phosphorylation and how this phosphorylation was regulated. However, in the first
part of my thesis study, we have demonstrated that Akt can be conjugated with nonproteolytic ubiquitination when cells were treated with known inducers for Akt activation
such as growth factors or cytokines (152, 158). Ubiquitination of Akt is well correlated
with phosphorylation of Akt at Thr308 and activation of Akt. Remarkably, this
ubiquitination

acts

through

K63-linked

but

not

K48-linked

polyubiquitination.

Ubiquitination of Akt does not change stability of Akt, but it is critical for activating Akt
signaling pathway (152, 158).
Following experiments in my study identified that TRAF6 is an E3 ligase for
ubiquitination of Akt. Traf6-/- primary MEFs exhibited deficiencies in ubiquitination and
phosphorylation of Akt in response to growth factors including IGF-1 and serum treatment
(152, 158). Reconstitution of TRAF6, but not TRAF6 E3 enzyme dead mutant, restored
ubiquitination and following phosphorylation of Akt in Traf6-/- MEFs, suggesting that
TRAF6 E3 enzyme activity is essential for phosphorylation and activation of Akt (152,
158). The advanced mutation analysis demonstrated that ubiquitination of Akt took place
at lysine 8 (K8) and lysine 14 (K14) within the PH domain of Akt, and mutations on these
sites (from lysine to arginine) abolished phosphorylation and activation of Akt (152),
underlining the important function of ubiquitination in activation of Akt signaling.
Therefore, ubiquitination of Akt is characterized as a novel post-translational modification
which has a critical role in activation of Akt.
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Recent studies support our findings in PI3K/Akt signal transduction field. For
example, one study demonstrated that the role of growth arrest and DNA damage-inducible
a (GADD45a) in the regulation of Akt activation induced by mechanical stress. This study
found that increased mechanical stress in epithelia cells promoted Akt phosphorylation
through TRAF6-mediated K63-linked ubiquitination of Akt, leading to membrane
translocation and activation of Akt (159). Our group also reported that another ubiquitin
E3 ligase Skp2-SCF complex promoted K63-linked ubiquitination of Akt through EGFR
signal transduction pathway (153), suggesting that K63-linked ubiquitination of Akt can be
formed by different E3 ligases in response to distinct growth factor signaling pathways.
Indeed, our notion is further corroborated by discovery of NEDD4-1 as an E3 ligase for
K63-linked ubiquitination of Akt. The study found that upon stimulation with IGF-1,
NEDD4-1 promoted K63-linked ubiquitination of Akt, and this type of ubiquitination
subsequently enhanced nuclear translocation of Akt (160). Therefore, these studies provide
more evidence to support the significance of K63-linked ubiquitination of Akt in Akt
signaling pathway. We foresee that more discoveries about mechanism and/or function of
K63-linked ubiquitination of Akt would be reported in the future.
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5-3. Membrane translocation of Akt is regulated by ubiquitination.
Currently, it is widely perceived that Akt resides in the cytosol and moves to the
plasma membrane in response to a variety of growth factor stimuli. The PH domain of Akt
is clearly required for Akt membrane translocation by binding PI(3,4,5)P3 phospholipid ,
however, it also has a critical role in interaction with other proteins required for Akt
membrane recruitment. Numerous Akt binding partners have been reported and known to
regulate the activation of Akt. Some Akt binding proteins such as JNK interacting protein
1 (JIP1) and T cell leukemia-1 (TCL1) have been found to interact with the PH domain of
Akt (10, 161, 162), suggesting that Akt PH domain may not only function for PI(3,4,5)P3
binding, but also serve a scaffold to recruit the crucial adaptors essential for membrane
translocation and phosphorylation of Akt. This concept has been corroborated by study
with ectopic expression of the PH domain of Akt. This study demonstrated that
endogenous phosphorylation of Akt in cells was inhibited, whereas the PH domain mutant
of Akt which lost potential to interact with other adaptor proteins but retained the
PI(3,4,5)P3 binding did not (148).
Although the PH domain of Akt is well recognized to associate with PI(3,4,5)P3 for
membrane translocation of Akt, it is still unknown in the initial step of how Akt
translocates to the plasma membrane, where it can interact with PI(3,4,5)P3 and is
subsequently phosphorylated by PDK1 and mTORC2. The current model of Akt activation
proposed by the Tsichlis group indicates that before Akt translocates to the plasma
membrane to bind to PI(3,4,5)P3, the inactive Akt in the cytosol may be required to
associate with the essential adaptors by using its PH domain, which then promote
membrane localization of Akt (148). This model has tested and supported by my thesis
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study that TRAF6 promotes K63-linked ubiquitination of Akt at K8 and K14 within its PH
domain, which is essential for membrane translocation and activation of Akt. (152, 158).
Remarkably, ectopic expression of TRAF6 in cells stimulates polyubiquitination,
membrane translocation and phosphorylation of Akt, whereas knockdown of TRAF6
protein level blocks these processes (152, 158). These results highlight the significant role
of TRAF6-mediated K63-linked ubiquitination of Akt in the membrane localization and
activation of Akt, suggesting the K63-linked ubiquitination has some critical regulatory
roles in protein trafficking and signaling activation (93, 94).
However, TRAF6 does not appear to affect the activity of plasma membrane residing
Akt. Since overexpression of TRAF6 could not further enhance phosphorylation of the
myristoylated Akt mutant, which constitutively translocates to the plasma membrane (our
unpublished data). TRAF6-mediated polyubiquitination of Akt does not change the
capability of Akt to bind to PI(3,4,5)P3, supporting the concept that ubiquitination of Akt
is unnecessary for binding to PI(3,4,5)P3 (152). Another observation in my thesis study
also supported this concept, it is found that mutation of the essential ubiquitination site of
Akt on the K8 residue, which is out of the PI(3,4,5)P3 binding pocket, does not change the
capability of Akt to associate with PI(3,4,5)P3 (152). The results of my study suggest that
both steps (K63-linked ubiquitination and PI(3,4,5)P3 interaction) are essential for
membrane translocation and phosphorylation of Akt, and K63-linked ubiquitination of Akt
could precede the PI(3,4,5)P3 binding on the plasma membrane (Fig. 3-10). Further studies
are required for delineating the detailed mechanism of membrane translocation of
ubiquitinated Akt and identifying the adaptor(s) which facilitate this process.
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5-4. Hyper-ubiquitination provides hyper-activation of the cancer-associated Akt
mutant
Recently, several studies reported a point mutation within the PH domain of Akt
(E17K) in a variety of human cancers, including breast and colon cancer (49-53). The
cancer-associated Akt E17K mutant exhibits a constitutive membrane recruitment and
phosphorylation of Akt at Thr308, probably caused by its enhanced PI(3,4,5)P3 binding,
leading to abnormal oncogenic potential in human cancers (56). Remarkably, in my study,
I have also discovered that the Akt E17K mutant exhibit enhanced K63-linked
ubiquitination, and abolishment of this ubiquitination resulted in a dramatic reduction in
membrane localization and phosphorylation of Akt (152, 158). These results suggest that
Akt E17K mutant obtains two significant properties (enhanced ubiquitination and
PI(3,4,5)P3 binding of Akt), which provide constitutive membrane localization and
phosphorylation of Akt. Consequently, the results of my study suggest that targeting
ubiquitination of Akt may provide potential strategies for human cancers therapy in the
future.
Aside from the Akt E17K mutant, another Akt mutant (Akt E49K) was recently
discovered in human bladder cancer (55). Like the Akt E17K mutant, this mutant also
shows hyper-phosphorylation and activation of Akt compared with wild-type Akt (55),
however the molecular basis of its hyper-activation is unknown up to now. Since the E17K
mutation located at the PH domain of Akt obtains an extra lysine residue for ubiquitination,
it will be exciting to examine in the future if the hyper-ubiquitination can also be detected
in Akt E49K mutant and provide potential oncogenic functions of the Akt E49K mutant in
human cancers.
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5-5. The novel regulatory role of TRAF6 in multiple signal transduction pathways to
promote activation of Akt
In addition to involvement in activation of NF-κB and p38 upon cytokines stimulation,
my thesis study demonstrates that TRAF6 E3 ligase also plays an essential role for growth
factor-mediated Akt signaling activation. TRAF6 promotes K63-linked ubiquitination and
activation of Akt upon growth factor stimulation (152, 158). Remarkably, IGF-1 receptor
(IGF-1R) signaling pathway elicits auto-ubiquitination and activation of TRAF6
corresponded with ubiquitination of Akt (152, 158). Furthermore, TRAF6 physically binds
to IGF-1R and this association is interrupted upon stimulation with IGF-1 (152, 158).
However, the mechanism of how IGF-1R signaling induces ubiquitination and activation
of TRAF6 remains unknown. Further studies are required to investigate the molecular
basis by which IGF-1R signaling promotes ubiquitination and activation of TRAF6.
From literature, we know that both endotoxin LPS and proinflammatory cytokine IL-1
promote cells survival through eliciting phosphorylation of Akt (163-165), although the
detailed molecular basis by which these stimulations promote activation of Akt is currently
unclear. The results of my thesis study offer the first evidence as to how LPS or IL-1
activates Akt. LPS or IL-1 stimulation acts through TLR4/IL-1R signaling-mediated
TRAF6 activation. Furthermore, activated TRAF6 initiates K63-linked ubiquitination,
phosphorylation and activation of Akt (152, 158). Therefore, my study suggests that
TRAF6 is involved in several critical signal transduction pathways in regulating
inflammation, innate immune response cell growth and survival. However, we need further
studies to investigate the molecular basis of growth factor receptor signaling pathwayinduced TRAF6 activity and to clarify the cross-talk between growth factor and TLR4/IL126

1R signaling pathways in the regulation of TRAF6 activity and subsequent activation of
Akt.

127

5-6. The potential oncogenic role of TRAF6 in tumorigenesis
Even though the deregulated NF-κB signaling pathway is obviously related to human
cancer development (166, 167), it is unknown whether the central mediator of this
signaling pathway, TRAF6, is also engaged in tumorigenesis. Recent studies have
implicated the involvement of TRAF6 in human cancer development. It is shown that
TRAF6 associates with an adaptor protein p62 and their interaction is essential for
ubiquitination and activation of TRAF6 (168). p62 is an oncogenic Ras responsive protein
which protein level can be upregulated by Ras and is critical for Ras-mediated activation of
NF-κB, cell transformation and lung cancer development (169).
Interestingly, my thesis study provides the more direct evidence regarding the
potential role of TRAF6 in tumorigenesis. My study demonstrates that TRAF6 deficiency
in prostate cancer cells decreases phosphorylation and activation of Akt induced by IGF-1
and diminishes tumorigenic potential of prostate cancer cells in the xenograft animal model
(152). This finding extends the role of TRAF6 from toll-like receptor signaling and innate
immune response to growth factor and oncogenic signaling pathways. Therefore, my study
proposes that TRAF6 is a previously unidentified oncoprotein which has a critical role in
human cancer development and progression. Indeed, recent studies support this notion that
TRAF6 has oncogenic functions involved in several human cancers such as breast cancer,
lung cancer, gastric cancer, prostate cancer and acute myeloid leukemia (170-174).
Accordingly, targeting TRAF6 protein or E3 ligase activity may be a promising strategy
for human cancer therapy.
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5-7. The role of deubiquitinase CYLD in regulating Akt signaling pathway
The second part of my thesis study provides the insight into the mechanism of
deubiquitination of Akt. We discovered CYLD as a crucial DUB which retains Akt in a
hypo-ubiquitinated and inactive status. Subsequently, CYLD deficiency increases basal
K63-linked ubiquitination of Akt and following membrane translocation and activation of
Akt, thus enhancing oncogenic functions of Akt, such as cell proliferation, cell survival,
and glucose uptake (175). Recently, Lim and colleagues (176) reported that CYLD
suppresses TGF-β-induced lung fibrosis by reducing stability of Smad3 and K63-linked
ubiquitination of Akt. Their study supports our finding that CYLD is a DUB for
deubiquitination of Akt, and CYLD regulates biological functions of Akt through
deubiquitination. However, this study did not provide any clue whether CYLD suppresses
growth factor-mediated ubiquitination, membrane translocation and activation of Akt to
further promote cancer development.
In my study, we discovered that CYLD binds to Akt under serum-free situation but
this association is separated upon stimulation with growth factor. However, ubiquitination
and phosphorylation status of Akt does not affect the association between CYLD and Akt
(175). In addition, we examined that PI3K activity, which is critical for growth factorinduced activation of Akt, is unnecessary for ubiquitination of Akt elicited by growth
factor and deubiquitination of Akt induced by CYLD (175). Although PI3K activity has a
dispensable role in ubiquitination/deubiquitination processes of Akt, it is still essential for
the phosphorylation of hyper-ubiquitinated Akt E17K mutant (175).
Recently, our group also demonstrated that another Skp2-SCF E3 ligase promotes
K63-linked ubiquitination of Akt through EGFR signaling pathway (153). In addition,
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another group discovered that NEDD4-1 is an E3 ligase for K63-linked ubiquitination of
Akt through IGF-1R signaling pathway (160). Therefore, it is very interesting to know
whether CYLD can also remove other E3 ligases-mediated K63-linked ubiquitination of
Akt upon stimulation with distinct growth factor signaling pathways. Indeed, my study
demonstrates that CYLD also efficiently removed Skp2-mediated ubiquitination of Akt,
and CYLD deficiency cells also showed enhanced membrane recruitment and
phosphorylation of Akt (175). Thus, our results support the concept that CYLD may play a
universal deubiquitinase for removing K63-linked ubiquitination of Akt induced by
different E3 ligases in distinct growth factor signaling pathways.
Based on the working model that I proposed in the second part of my study (Fig. 4-8),
CYLD binds to Akt in the cytosol under the quiescent status to prevent the interaction of
E3 ligases with Akt and also keep Akt under hypo-ubiquitinated status. Growth factor
signaling triggers separation of CYLD from Akt and interaction of the E3 ligases with Akt
to allow the E3 ligases-mediated ubiquitination of Akt. However, we still do not know
whether the separation of CYLD from Akt results from competition binding of the E3
ligases or whether growth factor-mediated certain modification on CYLD directly leads to
the disassociation of CYLD with Akt. Since this working model was established by the
experiments of IGF-1 signaling-mediated association of Akt with TRAF6, we do not know
whether this working model would be applicable to explain the mechanism of Skp2mediated ubiquitination of Akt in EGFR signaling pathway. Further studies are needed to
delineate the detailed mechanism of how growth factor signaling pathways regulate the
disassociation of CYLD with Akt to trigger E3 ligase-mediated ubiquitination of Akt.
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5-8. The potential tumor suppressive mechanism of CYLD in human cancers
My thesis study discovered for the first time the previous unrecognized role of CYLD
in growth factor-induced ubiquitination, membrane translocation and activation of Akt. In
addition, we demonstrate novel functions of CYLD in regulating glucose uptake,
membrane localization of glucose transporter 1 (Glut1) and prostate cancer development,
thus providing new exemplars for development, progression and treatment of human
cancers. Although several clinical studies showed that CYLD protein level was reduced in
human melanoma, liver cancer and colon cancer (151), its role in prostate cancer
development remains a puzzle. In my study, we revealed that CYLD knockdown enhanced
prostate

cancer

progression

in

a

xenograft

animal

model.

Furthermore,

immunohistochemistry results for clinical prostate cancer patient sample exhibited that
CYLD protein level was declined in advanced-stage of prostate cancer samples and
reversely associated with activation of Akt (175). Therefore, our findings suggest that
CYLD may serve as a tumor-suppressor in prostate cancer development by suppressing
oncogenic Akt signal transduction pathway.
CYLD is also well known to negatively regulate activation of NF-κB through
deubiquitination of several important mediators for NF-κB signaling activation including
TRAF2, TRAF6 and NEMO (67, 122, 125-128). Since NF-κB signaling also plays an
important role in human cancer development (177), it is possible that tumor suppressive
functions of CYLD are not simply through regulating activation oncogenic Akt signaling.
Indeed, two recent studies support this notion. A study reported that mRNA expression and
protein level of CYLD were reduced dramatically in most human tumor samples including
colon and liver cancers. In addition, reconstitution of CYLD expression in these tumor cell
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lines markedly reduced the activity of NF-κB (178), suggesting a potential tumor
suppressive role of CYLD in development of human cancers through inhibiting NF-κB
signaling activation. Another study demonstrated that loss of CYLD expression resulted in
constitutive NF-κB and MAPK signaling activation in hepatocytes, leading to apoptosis,
inflammation and chronic liver diseases such as fibrosis and hepatocellular carcinoma
(HCC) (179, 180). These results are consistent with my studies. We found that CYLD
deficient prostate cancer cells treated with PI3K inhibitors impaired the increase in cell
growth and survival, however the inhibitory effect was not complete, indicating that
additional signaling pathways which regulate cell proliferation and survival controlled by
CYLD may exist (175). Since we did not investigate the role of CYLD in activation of NFκB signaling in my study, we cannot exclude the possibility that CYLD may negatively
regulate both oncogenic Akt and NF-κB signaling pathways in human cancer development
and progression. Further studies are needed to delineate how CYLD plays a decisive tumor
suppressive role through inhibiting Akt and NF-κB signaling pathways in human cancers.
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Chapter 6
Future Direction
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In this thesis study, we demonstrated that Akt can be conjugated with K63-linked
ubiquitination by growth factor signaling pathway. This modification is required for
membrane recruitment and subsequent activation of Akt, and this novel regulation can be
reversed by the specific deubiquitinase. Our findings provide direct evidence that
ubiquitination of the critical signaling mediators downstream of growth factor receptors is
also essential for protein trafficking and signal pathway activation. This significant
discovery sheds new light on the PI3K/Akt signaling field, suggesting that ubiquitination
of Akt may also paly similarly significant role as phosphorylation does on Akt. We foresee
that the research focus on the regulation of ubiquitination of Akt and its role in human
cancer development and progression represent brand-new and significant areas for further
understanding of growth factor signal transduction pathways. Therefore, it is expected that
more and more exciting and significant discoveries in this area will be made in the coming
decade.
However, the fundamental roles of ubiquitination/deubiquitination cycles on distinct
cellular functions remain unknown. The importance of this post-translational modification
warrant further investigations. Answering these questions will not only allow us to better
comprehend the complicity of ubiquitination cycle in Akt signaling activation, but also
open a novel and exciting avenue of the role of ubiquitination in the regulation of growth
factor signal transduction pathways. Here, I listed some of important questions for the
future research direction:
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6-1. How do growth factor signal transduction pathways regulate activity of TRAF6
E3 ligase and CYLD deubiquitinase?
In the first part of my thesis study, we have demonstrated that IGF-1R signaling
pathway promotes auto-ubiquitination, and activation of TRAF6 correlated with
ubiquitination of Akt (152). However, it is still unclear how IGF-1R signaling promotes
ubiquitination and activation of TRAF6. My study showed that TRAF6 physically
associates with IGF-1R and this interaction is disrupted by IGF-1 signaling (152). Since
protein phosphorylation is well-known to regulate protein activation, it is possible that
TRAF6 may undergo phosphorylation by IGF-1R tyrosine kinase upon stimulation with
IGF-1. Indeed, I have demonstrated that IGF-1 treatment promoted tyrosine
phosphorylation of TRAF6 (my unpublished observation). A recent study also supported
this hypothesis that TLR4 signaling promotes the association of TRAF6 with Src family
kinases including c-Src and Fyn. This interaction causes tyrosine phosphorylation of
TRAF6 by Src family kinases and following activation of TRAF6 (181). This study
suggests that IGF-1-induced activation of TRAF6 may be mediated through receptor
tyrosine kinase or Src family kinases. Since another E3 ligase Skp2 had been reported
previously that it can be phosphorylated by Akt and this phosphorylation promotes Skp2
E3 ligase activity (37, 38), it is also highly possible that TRAF6 may also undergo
phosphorylation by EGFR family kinase or other kinases in EGFR signaling pathway.
Similar to the E3 ligases for Akt, the activity of CYLD deubiquitinase may also be
regulated by growth factor signaling pathways. Based on the working model in the second
part of my study, CYLD disassociates with Akt upon activation of growth factor signaling
(Figure 4-8). However, how growth factor signaling induces the disassociation of CYLD
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with Akt is still unknown. CYLD had been also reported previously to be phosphorylated
by IKK family members and this phosphorylation inhibits CYLD enzyme activity (182,
183). These studies provide a hint that CYLD may undergo phosphorylation by growth
factor receptor kinases or other kinases in growth factor signaling pathways, and this
phosphorylation may either inhibit CYLD enzyme activity or induces the separation of
CYLD from Akt.
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6-2. What is the molecular basis of K63-linked ubiquitination in membrane
recruitment and activation of Akt?
In the first part of my thesis study, we had demonstrated that TRAF6-mediated K63linked ubiquitination of Akt upon stimulation with growth factor, and this modification is
required for membrane recruitment, phosphorylation and activation of Akt (152). However,
one outstanding question remains to be answered: how does the ubiquitination control
membrane translocation of Akt? As the K63-linked ubiquitination has a critical function in
protein/protein interaction, the K63-linked ubiquitination on the PH domain of Akt may
work as a molecular scaffold to attract the crucial adaptors to promote membrane
translocation and activation of Akt. To validate this hypothetical model, a comprehensive
analysis towards identifying the candidates for Akt adaptor by using some systematic
approaches is required. It may help us to understand how K63-linked ubiquitination
controls membrane localization and activation of Akt. For example, a recent study showed
that p21 protein (Cdc42/Rac)-activated kinase 1 (PAK1), a protein kinase involved in cell
migration and tumorigenesis (184) associates with Akt and facilitated membrane
translocation of Akt (185). How precisely PAK1 controls membrane translocation and
activation of Akt is still a mystery up to now. In the future direction, it will be very
interesting to investigate if ubiquitination of Akt coordinates the binding between PAK1
and Akt, then facilitating membrane translocation of Akt.
From literatures, we speculate that such adaptors for Akt are probably ubiquitinbinding proteins, which include ubiquitin-binding domains competent of interacting with
mono-ubiquitin or different kinds of polyubiquitination chain (186). A variety of ubiquitinbinding domains were identified recently, including ubiquitin-associated domain,
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ubiquitin-interacting motif, Npl4 zinc-finger domain, polyubiquitin-associated zinc-finger
domain, GRAM-like ubiquitin binding in Eap45 domain, coupling of ubiquitin conjugation
to endoplasmic reticulum degradation domain and ubiquitin conjugating enzyme variant
motif (186). In addition to ubiquitination, ubiquitin-binding proteins are also discovered to
be engaged in protein degradation, endocytosis of receptor, DNA damage response and
protein kinase activation (186). Thus, a protein which contains such ubiquitin-binding
domains may be considered as a candidate of Akt adaptor protein.
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6-3. Is it feasible to develop a novel strategy by targeting ubiquitination of Akt for
human cancer therapy?
As mentioned before, the activities and functions of oncogenes and tumor suppressors
essential for cell growth, survival and tumorigenesis are controlled by ubiquitination and
deubiquitination regulated by the E3 ligases and DUBs, respectively. Significantly,
deregulation of the E3 ligases and/or DUBs is commonly discovered in various human
cancers (69, 75, 187, 188). In addition, several mouse caner models have demonstrated
significant roles of the E3 ligases and DUBs in cancer development and progression(69, 75,
187, 188), suggesting that E3 ligases or DUBs may be ideal drug targets for developing
effective therapeutic for human cancer in the future.
Akt signaling pathway is a well-known and significant oncogenic event in cancer
development. Clinical evidence support this notion that abnormal Akt activation is
correlated with numerous human cancers (9, 10, 38, 189). Given the significant role of the
Akt signaling in human cancers, small-molecule inhibitors which target Akt kinase activity
have been developed and tested in several clinical trials (66, 190, 191). Since TRAF6 has
been demonstrated as a crucial E3 ligase for ubiquitination, membrane localization and
activation of Akt in my thesis study. Small molecules targeting TRAF6 E3 ligase activity
may be appealing as single or adjuvant agents for human cancer therapy. Consistent with
this concept, TRAF6 deficiency in prostate cancer cells decreases activation of Akt and
development of prostate cancer (152). In addition, TRAF6 knockdown reduces the ability
of chemotherapy resistance in prostate cancer cells (152). Thus, our findings suggest that
TRAF6 targeting may be also applied with chemotherapy agents as a combinational
approach to enhance the susceptibility of cancer cells.
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Apart from developing small molecule inhibitors for TRAF6 targeting, the regulation
of the microRNA (miR) pathways that negatively control TRAF6 protein expression may
also be considered. Recent studies support this concept that miR-145 and miR-146a were
demonstrated to suppress protein translation of TRAF6 and exhibited a potential tumorsuppressive function in restraining the progression of primary and metastatic breast cancer
(170, 171, 192). Therefore, these results suggest that it may also be considered to
manipulate miR-145 and miR-146a as a novel therapeutic strategy for human cancer
therapy.
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